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ABSTRACT
Joint disease, particularly osteoarthritis, is a major cause of lameness and loss of 
athletic performance in the equine industry. Much interest therefore, has focussed 
on the use of biochemical markers, such as keratan sulphate, a proteoglycan of 
articular cartilage, as a means of evaluating cartilage and diagnosing 
osteoarthritis.
In the current study, keratan sulphate was measured using an ELISA (used in 
human medicine) which was validated for the horse. The assay results were 
found to be reproducible from day to day and the assay itself was technically 
convenient to carry out. There was evidence of non-parallelism between the 
standard curve and equine serum samples, however, this did not make a 
significant difference to the concentrations of keratan sulphate measured. 
Synovial fluid and serum levels of keratan sulphate were evaluated in a group of 
eleven normal horses. There was no correlation between serum and synovial fluid 
keratan sulphate levels in these animals. There was no difference in synovial 
fluid keratan sulphate levels measured in paired carpal and tarsal joints in all 
eleven animals. There was a consistently greater level of keratan sulphate in the 
left radiocarpal joint compared to the left midcarpal/carpometacarpal joint in all 
horses, however this data may have been biased due to the relatively small 
sample number. There was no evidence of day to day or diurnal variation in a 
group of normal ponies used in the current study, suggesting that a single 
measurement of keratan sulphate represents a steady state. In a group of six 
racehorses in training, sampled before and after a period of acute (60 min) 
exercise, there was a significant elevation in serum keratan sulphate levels, 
however, this finding was not repeatable on a second test. As only four of the 
original six horses were available for sampling, the small sample number may 
have influenced the results obtained on this second test. Serum keratan sulphate 
levels were evaluated in three horses with osteoarthritis that were treated 
surgically. There was an elevation in serum keratan sulphate levels two days 
post-operatively in response to surgical intervention. This finding is in agreement 
with the results of other authors. However, it was only possible to monitor two of 
these horses for four days post-operatively, by which time, serum keratan 
sulphate levels were starting to decrease. In one of these cases, in which serum 
keratan sulphate was measured for 106 days post-operatively, levels remained 
consistent and were lower than the values recorded pre and intra-operatively. 
They did not appear, in this one animal, to be affected by a return to exercise 
(uncontrolled) and resumption of training. It was concluded that longitudinal 
sampling to evaluate serum keratan sulphate or synovial fluid keratan sulphate is 
likely to be of greater value in evaluating articular cartilage status than one-off 
measurements. Used in conjunction with other tests/biochemical markers, it may 
provide some useful information on articular cartilage metabolism in vivo.
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CHAPTER I
INTRODUCTION
Orthopaedic conditions have been shown to be the major cause (68 per 
cent) of loss of racing performance in horses in the British racing industry 
(Rossdale, Hopes, Wingfield-Digby and Offord 1985). These authors found 
that 28 per cent of lameness was attributed to joint disease.
Following appropriate conservative or surgical treatment for acute joint injury 
due to trauma, or following certain forms of osteochondrosis, many horses 
achieve complete functional recovery. However, a proportion of these animals go 
on to develop secondary arthrosis, i.e. degenerative joint disease (DJD), also 
referred to as osteoarthritis (OA). This condition has been shown to be a major 
cause of loss of use in athletic performance horses (Mcllwraith and Vachon
1988).
OA is ubiquitous in current and past animal and human populations. It is the 
most common joint disease of man and a major cause of economic loss due to 
disability (Brandt 1991). Evidence of OA can be found on radiographs of 70 to 
80 per cent of people over the age of 55 years, (Brandt 1991), although many 
patients are asymptomatic (Lane, Michel, Bjorkengren, Oehlert, Shi, Bloch and 
Fries 1993). The relative age of equine patients (2 years old to 18 years old, 
Todhunter and Lust 1992) is younger compared to humans. The expectations of 
therapy are greater in equine patients compared to humans, with complete 
restoration of normal joint function ultimately demanded for the equine athlete.
It is currently unknown at which stage articular cartilage damage becomes 
irreversible. Articular cartilage, once damaged, has a very poor capacity for 
intrinsic repair. It is the key to the functional integrity of the joint. Much interest, 
therefore, has focused on the biology of this tissue in health and disease and the 
development of methods to diagnose and monitor the response of articular 
cartilage to injury as early as possible in the course of disease.
1. ARTICULAR CARTILAGE
1.1 Biology of articular cartilage
Articular cartilage is a dynamic biologic tissue. The major organic components of 
articular cartilage are Type 2 collagen (85 to 90 per cent of the total) (Mayne and 
Irwin 1986) and large aggregating proteoglycans (PG) (aggregan). Proteoglycans 
are enmeshed at a high concentration in a dense network of collagen fibres 
(Thonar, Bjomsson and Kuettner 1986a). The Type 2 collagen fibrillar network is 
essential for maintaining the tissue's volume and shape. It gives articular cartilage 
its tensile strength, a property enhanced by the presence of cross-links, mostly of 
the pyridinoline class (Eyre, Dickson and Van Ness 1988).
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The physiological function of articular cartilage is to resist compression and aid 
in the dissipation of forces applied to the joint during weightbearing and 
movement. The high concentration of PGs within the cartilage helps to maintain 
the collagen network under tension, allowing the tissue to adapt to changes in 
load and weightbearing. The elastic properties of normal joint cartilage thus 
result from interactions between the PGs and the collagen network.
Cartilage owes its resistance to compression to the electrostatic repulsion of its 
thousands of adjacent negatively-charged sulphate and carboxyl groups on the 
PG molecules. The spaces between the chains of the PG molecules are filled with 
water, the protons of which are attracted to the negatively charged sulphate 
groups of the chondroitin sulphate and keratan sulphate chains of the PGs. 
Approximately 80 per cent of the total weight of normal mature articular cartilage 
is water, with chondrocytes forming only one to two per cent of the tissue 
volume (Todhunter and Lust 1992).
1.2. Biology of Proteoglycans
Proteoglycans, the second of the 2 major organic components of the joint, are the 
key to the integrity of the articular cartilage. PGs are a diverse group of 
heterogenous complex macromolecular glycoconjugates. They exist as multiple 
populations with considerable polydispersity (Thonar and others 1986a). They 
are defined as proteins that contain one or more covalently attached 
glycosaminoglycan (GAG) sidechains (Kuettner, Aydelotte and Thonar 1991).
Their selective distribution in various anatomic sites, the diversity of their 
structure and the changes they undergo with age suggest they have specialised 
functions within the cartilage. These variations in the distribution of collagen and 
PGs within the articular cartilage may be genetically determined and appear to be 
characteristic of each individual cartilage (Muir 1978).
The predominant PG in articular cartilage is aggregan, the large aggregating PG 
which constitutes approximately 80 per cent of the total PG (Lohmander 1988). 
Aggregan may help to protect PGs from proteolytic degradation (Heinegard and 
Hascall 1974) or it may function to inhibit cartilage calcification. The remaining 
PGs are associated with collagen and appear to give cartilage its mechanical 
stability (Brandt 1981). Dermatan sulphate PGs are also present in articular 
cartilage and occur as two species of different molecular weight (Rosenberg, 
Choi, Tang, Johnson, Pal, Webber, Reiner and Poole 1985). As compared with 
PGs specific to cartilage, monomers of dermatan sulphate are much smaller and 
do not bind to hyaluronan to form large stable aggregates. Instead they self­
associate to form relatively small, unstable aggregates (Rosenberg and others 
1985). The large cartilage PG monomer (aggregan) contains typically some 80 to 
100 chondroitin sulphate (CS) chains, 30 keratan sulphate (KS) chains, 50 O- 
linked oligosaccharides and 5 to 10 N-linked oligosaccharides. Each KS chain 
consists of a linear repeat of disaccharides of N-acetylglucosamine and galactose, 
(Figure 1) where the hexosamine and sometimes also the galactose, carries a 
sulphate in the 6-position.
Figure 1
Aggregan with tentative structure of antigenic and nonantigenic KS chains.
The longest KS chain shown here contains two contiguous epitopes and can bind at 
least two antibody molecules. Negatively charged sulphate groups on galactose and 
N-acetlyglucosamine are shown as short vertical lines.
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The linkage of KS to protein is via a glycosidic bond between serine/threonine 
and N-acetylgalactosamine (Hopwood and Robinson 1974). Following synthesis 
of the core protein in the endoplasmic reticulum of the chondrocyte and addition 
of GAG chains in the Golgi (Kimura, Thonar and Hascall 1981), the monomeric 
aggregating PGs are secreted into the extracellular matrix where they become 
incorporated into aggregates by binding specifically and non-covalently via their 
hyaluronate binding (HB) region with a small segment of the hyaluronan 
molecule (Kimura, Hardingham, Hascall and Solursh 1979). A third protein, link 
protein, also synthesised by the chondrocyte stabilises the attachment of each 
monomer to hyaluronan by interacting with both hyaluronan and the HB region 
of the core protein (Kimura and others 1979). The individual aggregates contain 
about 40 PG monomers.
The core protein contains three distinct globular domains, (G1 to G3) 
(Hardingham, Beardmore-Gray, Dunham and Ratcliffe 1986). Most GAG chains 
are clustered between G2 and G3. The largest region, the CS rich region, 
contains more than 50 per cent of the core protein and almost all the CS. The 
majority of the KS chains are located in the intermediate region of the core 
protein. These chains vary in molecular weight from 2000 to 8000. There are 
approximately 40 KS chains per molecule (Lohmander 1988).
1.3 Biology of keratan sulphate
More than 95 per cent of the mass of KS in the body is located in hyaline 
cartilage (including the intervertebral disc) v.ith the balance in cornea, bone and 
other tissues (Thonar, Williams, Sweet, Maldonado, Lenz, Schnitzer and 
Kuettner 1988a). Two types of KS occur in mammals, comeal KS (Type 1) and 
skeletal KS (Type 2). They differ from each other in their average degree of 
sulphation (Type 2 is more sulphated than Type 1) and in their linkage to protein 
(N- and 0- linked respectively) (Caterson, Brooks, Sattsangi, Ratcliffe, 
Hardingham and Muir 1989).
Aggregating PGs of human articular cartilage are relatively rich in KS (Roughley 
and White 1980). This is true of other vertebrate species in general except PGs in 
mice and rats which do not appear to contain significant amounts of KS (Venn 
and Mason 1985). The concentration of KS varies from cartilage to cartilage and 
also within an area of cartilage (Thonar and others 1986a). PGs containing KS 
are present primarily in the more basal zones of articular cartilage (Aydelotte and 
Kuettner 1988). KS is a major component of mineralising calf bone (Meyer 
1956), but not of mature bone (Scott and Haigh 1985). It is present in arterial 
wall (Baker 1989) and in the GAG rich pressure pads of flexor tendons in small 
amounts (Vogel and Thonar 1988).
Keratan sulphates are typically heterogenous in size and charge, properties that 
have hindered isolation and characterisation of the KS molecule by standard
! biochemical techniques. Identification of the structure of KS has been facilitated
by the development of KS specific endoglycosidases (Baker 1989).
i
i
i
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The contribution of KS chains to the functional properties of the aggregating PGs 
of articular cartilage is unclear (Thonar and others 1986a). It is possible that the 
KS chains and related O-linked oligosaccharides offer some protection from 
proteolytic degradation of the core protein by extracellular proteases secreted by 
the chondrocytes. Although KS and to a lesser extent the O-linked 
oligosaccharides contribute to the functional properties of the PG, i.e. swelling 
pressure and resistance to deformation, this varies with age, tissue and species. 
KS content increases with age (Thonar and others 1986a) and is often higher in 
maximally loaded areas.
Sulphated KS may not be an essential ingredient for normal cartilage function, 
(Thonar, Meyer, Dennis, Lenz, Maldonado, Hassell, Hewitt, Stark, Stock, 
Kuettner and Klintworth 1986b). Most patients with Type 1 Macular Corneal 
Dystrophy, a disease caused by precipitation of unsulphated KS-bearing PG in 
the cornea, do not have normally sulphated KS in their circulation (Thonar and 
others 1986b). As patients with this condition do not have an increased incidence 
of cartilage disease, it is likely that the presence of sulphate groups on the keratan 
chains is not essential for the functional properties of cartilage PG (Thonar, 
Williams, Sweet, Maldonado, Lenz, Schnitzer and Kuettner 1989a). KS chains of 
normal length are absent from cartilages of rats and mice (Venn and Mason 
1985). Therefore sulphated KS chains provide little advantage even in cartilages 
subjected to very high loading forces.
2. METABOLISM OF ARTICULAR CARTILAGE
2.1 Metabolism of proteoglycans
Proteinases synthesised by the chondrocytes in inactive form are activated in the 
matrix and can cleave the core protein of individual aggregating molecules at one 
or more sites, but usually near the HB region (Figure 2). The fragments 
containing GAGs then rapidly diffuse out of the matrix into adjacent body fluids. 
The matrix of adult human cartilage becomes enriched with non-functional PG 
fragments consisting of a HB region to which few or no GAG chains are attached 
(Roughley, Poole, Campbell and Mort 1986; Bayliss, Holmes and Muir 1989). 
These GAG depleted degradation products represent up to 50 per cent of the PG 
molecules in the matrix (Bayliss and others 1989). The contention that the 
diffusion of GAG-bearing fragments from the matrix occurs soon after cleavage 
of core protein is supported by the observation that GAG-rich PG fragments are 
not found in significant amounts in the matrix (Kimura, Osdoby, Caplan and 
Hascall 1978).
As intact aggregating PG are not found in significant amounts in the body fluids 
in contact with the cartilage surfaces, measurement of peptidoglycans in body 
fluids provides a means of determining the rate of catabolism of cartilage PG. In 
vitro measurement of radioactive -^Sulphate (55S) labelled fragments in 
incubating ^S-labelled articular cartilage cultures have been used to determine 
the rate of catabolism or turnover of PG in the matrix (Barone-Varelas, Schnitzer,
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Meng and Thonar 1989). Measurement of KS by immunoassay provides a means 
of measuring cartilage metabolism in vivo.
The pathways by which PG fragments are metabolised in the body are unclear. 
They may be further degraded before entering the circulation, from which they 
are eliminated via the liver and kidneys (Thonar, Lenz, Klintworth, Caterson, 
Pachman, Glickman, Katz, Huff and Kuettner 1985). Most KS-bearing molecules 
in human blood consist of a single KS chain of varying length which is still 
attached to a small peptide (Thonar and others 1985). Maldonado, Williams, 
Otten, Flannery, Kuettner and Thonar (1989) showed that KS bearing PG 
fragments injected intravenously in rabbits are eliminated from the blood at 
different rates depending on their size and composition (half-life, 6 to 50 
minutes). The major pathway of elimination from blood may be by binding of 
fragments of KS containing terminal galactose residues to galactose receptors on 
hepatocytes (Schlepper-Schaffer, Hulsmann, Djovkar, Meyer, Herbertz, Kolb and 
Kolb-Bachofen 1986).
The level of serum KS can vary markedly from individual to individual (Sweet, 
Coehlo, Schnitlzer, Schnitzer, Lenz, Jakim, Kuettner and Thonar 1988; Seibel, 
Towbin, Braun, Kiefer, Muller and Paullson 1989). Hascall and Giant (1987), 
suggest that the extent of KS sulphation may vary considerably from person to 
person and that this could partly contribute to the wide range of values (53 to 
1,009 ng/ml) observed in human patients (Thonar, Manicourt, Williams, Lenz, 
Sweet, Schnitzer, Otten, Giant and Kuettner 1991a). Levels of KS vary 
predictably with age (Thonar, Pachman, Lenz, Hayford, Lynch and Kuettner 
1988b), rising progressively in the first four years of life in humans, dropping 
markedly at twelve years of age and continuing to decrease towards adult 
concentrations. The serum level of cartilage core protein epitope has a similar 
variation and in children shows a strong correlation with the level of serum KS. 
This adds strength to the opinion that the level of serum KS can be used to obtain 
a good measure of the rate of PG catabolism. PG and KS content remain 
relatively constant with increasing age in adult humans (Thonar, Williams, 
Maldonado, Lenz, Sweet, Schnitzer, Campion and Kuettner 1991b) and it is 
concluded therefore that measurement of the level of serum KS can be used as a 
measure of basal PG turnover in individuals without cartilage disease in vivo.
2.2 Turnover of articular cartilage in health and disease.
Maintenance of both the quality and quantity of articular cartilage matrix 
components and adaptation to functional demands is the result of a balance 
between the synthetic and catabolic activity of the chondrocyte. The chondrocyte 
is actively involved in the metabolism of PGs throughout the lifetime of the 
tissue (Handley, Me Quillan, Campbell and Bolis 1986).
PGs in cartilage are constantly being turned over. Cartilage PGs turn over more 
rapidly than the collagen matrix in which they are embedded. Collagen turnover 
times are very slow; one hundred and twenty years in canine articular cartilage 
and three hundred and fifty years in human articular cartilage (Akizuki, Mow,
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Muller, Pita, Howell and Manicourt (1986). There are fast and slow pools of PG 
turnover; the overall turnover time in adult canine and lapine articular cartilage is 
approximately three hundred days and in the human hip joint it is eighteen 
hundred days (Todhunter and Lust 1992).
The degradation of PGs during normal turnover is regulated by the chondrocytes, 
which release proteolytic enzymes into the extracellular milieu. PGs and 
hyaluronan have similar half-lives, suggesting that the PGs within an aggregate 
are usually turned over as a unit. To maintain the balance, any normal or 
increased loss of proteoglycan from the matrix must be compensated for by de 
novo synthesis of PG by the cells within the tissue. If this compensatory 
synthesis fails, then the resistance of the tissue to load will decrease. It has been 
shown experimentally that healthy chondrocytes monitor the matrix content of 
PG and can respond rapidly to changes in their concentration in the extracellular 
matrix (Thomas 1956). This is believed to be mediated by cell surface 
interactions (Handley and Lowther 1977). There are many other endogenous and 
exogenous factors that may alter the rate of synthesis of matrix components by 
chondrocytes (Treadwell and Mankin 1979).
The turnover of normal articular cartilage is effected through a degradative 
cascade, for which many authors think the driving force is interleukin-1 (IL-1). 
This cytokine can stimulate production of, and secretion into the matrix of latent 
collagenase, latent stromelysin and latent gelatinase. It has been demonstrated in 
vitro, that after addition of IL-1 to cartilage explants, release of PGs into the 
culture medium occurs within hours (Saklatvala, Pilsworth, Sarsfield, Gavrilovic 
and Heath 1984). It can also stimulate production of prostaglandin E2 , a mediator 
of acute inflammation.
IL-1 is produced by the mononuclear cell system, including synovial lining cells 
in the joint, and is also synthesised by chondrocytes as an autocrine activity. IL-1 
activity may be controlled both by alterations in its production and alterations to 
endogenous levels of inhibition of its activity (Wood, Ihrie, Dinarello and Cohen 
1983). Articular cartilage also contains a family of neutral metalloproteinases 
capable of degrading PG (Brandt 1991). Net expression of proteolytic activity of 
neutral metalloproteinases represents a balance between activation of their latent 
forms and inhibition of the activity by inhibitors (Figure 3).
The balance of the system lies with at least 2 inhibitors, tissue inhibitor of 
metalloproteinase (TIMP) and plasminogen activator inhibitor (PAI-1), both of 
which are synthesised by the chondrocyte and limit the degradative activity of 
active neutral metalloproteinases and plasminogen activator respectively (Brandt 
1991). Conversion of latent stromelysin to active, highly destructive proteases by 
plasmin provides a second mechanism for matrix degradation. Cathepsin B and D 
(Bayliss and Ali 1978) are also very effective at degrading cartilage PG as are 
oxygen free radicals synthesised by the chondrocytes.
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Turnover of proteoglycans: role of proteinases in proteoglycan degradation
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2.3. Repair of articular cartilage
An increasing number of growth factors found to influence the metabolism of 
chondrocytes have been identified (Handley, Lowther and Me Quillan 1985). 
Insulin-like growth factor (IGF-1) appears to be one of the strongest factors for a 
physiological role in the regulation of cartilage metabolism by being present in 
normal serum and causing a marked stimulation of PG synthesis (Burch, Weir 
and Van Vyk 1988). Transforming growth factor beta, (TGF fl), has a paracrine 
and autocrine regulatory function and may play a role in matrix repair in OA 
(Brandt 1991). It is currently unknown whether age-related changes in the 
cartilage influence IGF-1 activity, or affect the responsiveness of the chondrocyte 
to these mediators.
In addition to its responsiveness to cytokines and a variety of other biological 
mediators, it is clear that chondrocyte metabolism can also be modulated directly 
by mechanical loading. Support for the ability of cartilage chondrocytes to 
respond directly to altered mechanical loading of the joints is given by animal 
models. Increased loading of the joints leads to increases in PG biosynthesis 
(Caterson and Lowther 1978). Prolonged immobilisation of joints may lead to 
degenerative changes and arthrosis (Eronen, Videman, Friman and Michelsson 
1978). Whereas static loading and prolonged cyclic loading inhibit synthesis of 
PG and protein, loads of relatively brief duration may stimulate matrix 
biosynthesis (Gray, Pizzanelli, Grodinsky and Lee 1988).
Little information is available about the in vivo rate of release of the PG 
fragments from joint cartilage. Experiments with cartilage explants in vitro 
indicate that the majority of the PG fragments generated by proteolytic 
breakdown are released from the tissues with only a small proportion (10 per cent 
or less) being taken up by the cells of the tissue (Hascall, Morales, Hascall, 
Handley and Me Quillan 1983).
3. OSTEOARTHRITIS
3.1. The pathogenesis of osteoarthritis
Osteoarthritis is a slowly progressing multifactorial disease of obscure aetiology. 
It has been argued that die OA process is a fundamental aspect of joint function. 
This function is as of yet not fully understood, but a widely held opinion is that it 
is part of the reparative response to joint injury (Jones and Doherty 1992).
Studies in humans have shown that there is an increased frequency of OA with 
age (Lane and others 1993). It has therefore been suggested that OA is a 
manifestation of aging in the joint, possibly reflecting senescence of joint 
function or the response to cumulative injury (Brandt 1981). However, it has 
been demonstrated that there are biochemical differences between old and 
osteoarthritic cartilage, implying that the explanation of aging may be too 
simplistic (Brandt 1988). In horses, animals as young as two years old may show
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evidence of advanced OA in several joints, leading to the suggestion that these 
animals may have an inherited biochemical abnormality of cartilage (May 1993 
unpublished). Todhunter and Lust (1992) comment on the fact that horses 
presenting with joint disease range from two years old to aged, suggesting that 
aging is not the primary cause of OA. Although certain studies in humans refute 
that mechanical factors correlate with OA (Panush, Smith, Caldwell, Edwards, 
Longley, Yonker, Webster, Nauman, Stork and Petterson 1986; Lane, Block, 
Jones, Marshall, Wood and Fries 1986), repetitive trauma has been shown to be 
an epidemiological factor in the development of the disease in humans (Peyron
1989).
One of the earliest biochemical changes occurring in osteoarthritic cartilage 
appears to be related to structural alterations in PG and collagen and the total 
content of these macromolecules in the cartilage. Although wear may be a factor 
in the loss of cartilage, strong evidence supports the concept of lysosomal and 
neutral metalloproteinases, (e.g. stromelysin, collagenase, gelatinase) accounting 
for the majority of the loss of cartilage matrix in OA. Increased levels of 
metalloproteinase have been found in osteoarthritic cartilage compared to 
controls (Martel-Pelletier, Pelletier, Cloutier, Howell, Ghandur-Mnaymneh and 
Woessner 1984). Cartilage fragments and other particles have the ability to 
stimulate production of neutral metalloproteinase and prostaglandin E2  by 
chondrocytes and synovial cells in vitro (Cheung, Halverson and Me Carthy 
1981). This forms a direct route by which the synthesis of enzymes responsible 
for cartilage degradation may be stimulated by traumatised joints (Evans, Mears 
and Cosgrove 1981).
Activation of cells of synovial membrane by e.g. trauma, may lead to production 
of IL-1 by activated cells which would stimulate the production of prostaglandin 
E2  and neutral metalloproteinases by chondrocytes, leading to pain and cartilage 
erosion. Increased production of cytokines in disease is due to lymphocytic 
activation, but can also be triggered by microbial products such as bacterial 
lipopolysaccharide (Arend and Massoni 1986). IL-1 and tumour necrosis factor 
(TNF) interact synergistically, and may induce their own and each other’s 
synthesis (Krane 1990) in addition to that of other cytokines, thereby providing a 
mechanism by which inflammation may persist in a joint. Endogenous inhibitors 
of IL-1 have been detected in serum, urine and cell culture supernatants in 
humans and appear to function as physiological modulators of IL-1 
(Rosenstreich, Yost, Tu and Brown 1987). It has been demonstrated that synovial 
fluid from horses with acute OA has inhibitory effects on IL-1 and IL-B 
stimulation of prostaglandin E2  production by equine synovial cells in vitro 
(May, Hooke and Lees 1992). Types or levels of inhibitors may vary in time with 
the course of the disease.
Biochemically, early structural alterations in osteoarthritic cartilage include a 
reduction of PGs, increased water content, chondrocyte cloning and an increased 
synthesis of matrix (Mankin, Johnson and Lippielo 1981). The new cells are very 
active metabolically, producing increasing quantities of collagen, PG and
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hyaluronan, although these new products have a reduced ability to form 
aggregates in general (Martel-Pelletier and others 1984). Prior to the loss of 
cartilage mass and PG depletion, marked biosynthetic activity (repair) of the 
chondrocytes may be associated with thickening of the cartilage in the earlier 
stages of OA. In the canine cruciate deficient model of OA, autoradiography with 
radiolabelled sulphate has shown that all cell have enhanced biosynthetic 
activity. (Thonar and others 1991a). This has been termed the hypertrophic repair 
phase of OA (Brandt 1991).
The degradation of articular cartilage is initially focal but may involve diffuse 
areas of the cartilage surface in advanced cases. As the disease progresses, the 
cartilage becomes ulcerated and there is development of fibrillation in the 
superficial layer, together with fissuring, osteophyte formation and sclerosis of 
the subchondral bone. Anabolic processes no longer keep pace with catabolism 
of the cartilage, resulting in an osteoarthritic joint.
3.2 Classification of osteoarthritis
Much confusion exists in both human and veterinary literature as to the 
classification of OA/degenerative joint disease. In veterinary literature, Me 
Ilwraith (1987) and May (1993, unpublished) have devised classification systems 
for the condition in horses (Table 1). Poole and Meagher (1990) describe OA in 
the horse as being primary, i.e. an idiopathic, age-related disease of insidious 
onset in which there is chronic deterioration of normal joint structure and loss of 
function, or secondary, i.e. occurring in previously normal joints following injury 
of these joints. In secondary OA, injury of the joint may occur at any stage 
following the primary insult. Another method of classifying OA is based on the 
possible adverse effects of biomechanical forces on normal and abnormal 
articulations (Mitchell and Creuss 1977). This scheme only recognises secondary 
causes of DJD. Irrespective of the classification system used, it is clear that 
degeneration and loss of the articular cartilage with concommitant joint failure as 
described above is the common end-point of this condition.
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Degenerative jo in t disease entities 
Type
1. Young, unbroken (2 years old) horses, advanced DJD in several 
joints. Possible inherited biochemical abnormality of cartilage.
2. Young racehorses, 2 to 4 years old. Acute disease in highly mobile 
joints.
3. Horses in light work, 4 to 8 years old. Insidious disease, distal limb 
joints with and without navicular disease.
4. Older horses, insidious disease of low motion joints.
5. Older horses, age changes unrelated to lameness.
May S.A. (1993) 
(unpublished)
Degenerative jo in t disease entities 
Type
1. Acute, associated with synovitis and high motion joints.
2. Insidious, associated with low motion joints.
3. Incidental or non-progressive articular cartilage erosion.
4. Secondary to other identified problems.
a. Intra-articular fractures.
b. Dislocations / ligamentous rupture.
c. Wounds.
d. Septic arthritis.
e. Osteochondrosis.
5. Chondromalacia.
Me Hwraith C.W. (1987)
Table 1
Classification of degenerative joint disease entities in the horse.
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3.3 Diagnosis of osteoarthritis
Apart from clinical signs such as pain, stiffness, and joint distension, 
radiography is the mainstay in the diagnosis of OA. In human medicine, the 
Kellgren and Lawrence grading system (1957) has been used in research on OA 
for over thirty years. This system relies heavily on radiographic evidence of 
osteophytes, with subsequent increase in grade being dependant on the 
concomittant loss of joint space radiographically. However, osteophytes may be a 
natural function of aging, in that articular cartilage alters its biomechanical 
makeup with age and the altered environment may favour degeneration of the 
articular cartilage and osteophyte formation (Hammerman 1989). Altman, Fries, 
Bloch, Carstens, Cooke, Genant, Gafton, Groth, Me Shane and Murphy (1987) 
found that joint space narrowing, followed by assessment of osteophytes were 
the best variables in judging the sequence of events. The correlation between 
symptom and structure is, however, poorly understood. Loss of 30 to 50 per cent 
of bone substance is required before radiographic detection of osteolysis is 
possible (Lodwick 1964). Thus, degenerative changes are well advanced before 
being detected radiographically. It has been shown that up to 40 per cent of 
humans with radiographic evidence of OA are asymptomatic (Lane and others 
1993). In horses, Jeffcott (1983) detected small bone spurs in a number of joints 
in a significant percentage of animals in regular work with no evidence of 
lameness. The lack of a clear relationship between clinical signs and presence or 
absence of radiographic abnormalities continues to be a problem for clinicians.
Christiansen (1985), using bone scintigraphy in human studies showed that only 
active non-specific joint involvement could be demonstrated and that this did not 
necessarily reflect progressive degenerative joint disease. Diagnostic arthroscopy 
and contrast arthrography are techniques also used in the diagnosis of equine 
joint disease. However, these techniques are invasive and animals are presented 
usually at a time when pathology within the articular cartilage is already well 
advanced. Arthroscopic and pathological studies serve to highlight potentially 
veiy important discrepancies between plain radiographic images and the actual 
situation within the joint in both humans (Fife, Brandt, Braunstein, Katz and 
Shelboume 1991) and horses (Nillson and Olsson 1973).
4. MARKERS OF JOINT DISEASE
4.1 Biochemical Markers of Joint Disease
From a diagnostic and therapeutic viewpoint, it would be preferable to have 
convenient and economical non-invasive tests that would indicate the metabolic 
or functional state of the synovium and cartilage at an early stage in the disease, 
before the onset of radiographic changes. There are several different sources and 
types of markers that have potential for use in the diagnosis of joint disease. 
These potential markers can be (a) anabolic markers, i.e. molecules that are only 
newly synthesised by the chondrocyte during the process of repair and 
remodelling (b) catabolic markers, i.e. those that are breakdown products or 
activated enzymes that cause release of these degradation products and (c)
23
general markers that occur as a consequence of increased catabolic and anabolic 
processes in the disease.
A number of assays for biochemical markers have been evaluated in the 
investigation of articular cartilage metabolism. Assays used for detection of joint 
disease focus on both synovial membrane and cartilage metabolism. Hyaluronan 
measurement has been carried out in humans (Goldberg, Lenz and Thonar 1988; 
Hedin, Weitoft, Hedin, Engstrom-Laurent and Saxne 1991) and horses (Hilbert, 
Rowley and Antonas 1984). Hyaluronan, however, is not specific to cartilage or 
to joints. Fibronectin has been measured in equine joint disease (Todhunter, Lust, 
Freeman and Parente 1990), and reported to be a useful indicator of joint disease 
severity and activity. IL-1 activity has been measured in equine joints as an 
indicator of disease activity (May and others 1992). Synovial fluid lysozyme 
activity correlates well with experimental inflammation or joint injury in horses 
(Torbeck and Prieur 1979). Collagenase activity (measured using synovial 
aldehyde groups) correlates with equine articular cartilage lesions at macroscopic 
level (Maldonado, Garces, Auba and Horvath 1983). Collagen breakdown 
products have been studied in the horse as potential markers of joint disease 
(Price, Colwell, Eastell, Goodship and Russell 1992). Antibodies against Type 
two collagen have been detected in synovial fluid and serum from humans 
(Mollenhauer, von der Mark, Burmester, Gluckelt, Lutjen-Drecoll and Brune 
1988) and horses with OA (Niebauer, Wolf, Yarmush and Richardson 1988).
4.2 Use of keratan sulphate as a biochemical marker in the evaluation of 
articular cartilage health status
The rational for measuring KS is based on the fact that more than 95 per cent of 
the mass of KS in the body is located in hyaline cartilage, and as such, it is 
reasonably cartilage specific (Thonar, Williams, Sweet, Maldonado, Lenz, 
Schnitzer and Kuettner 1989a). A polyclonal antiserum reacting with KS was 
initially characterised by Conrad, Ager-Johnson and Woo (1982) and shortly 
thereafter, mouse monoclonal antibodies against KS were isolated (Funderburgh, 
Stenzel-Johnson and Chandler 1983; Caterson, Baker and Christner 1983). 
Several other monoclonal antibodies against KS have subsequently been isolated, 
and have been shown to be highly specific for KS epitopes (Caterson and others 
1983; Ratcliffe, Doherty, Maini and Hardingham 1988). These antibodies have 
been used in the immunohistochemical localisation of KS in embryonic tissues 
(Hyldahl, Aspinall and Watt 1986; Funderburgh, Caterson and Conrad 1986) and 
via immunoassay for the detection of KS in human serum (Thonar and others 
1985) and equine serum and synovial fluid (Alwan, Carter, Bennet, May and 
Edwards 1990; Todhunter, Yeager, Freeman, Parente and Lust 1993).
The enzyme linked immunosorbent assay (ELISA) used in the current study is 
based on that of Thonar and others (1985), with several minor modifications 
(Thonar and others 1991b). The assay uses a mouse monoclonal antibody (MAb) 
(1/20/5/D4) (Caterson and others 1983). This antibody specifically recognises a 
sulphated antigenic determinant in the polysaccharide structure of both corneal
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and skeletal KS. It was shown by Caterson and others (1983), that the MAh did 
not recognise antigenic determinants on PGs isolated from Swarm rat 
chondrosarcoma. This finding is consistent with several biochemical analyses 
showing the absence of KS in PGs synthesised by this tissue. The MAb did not 
recognise determinants present in other GAGs such as dermatan sulphate, heparin 
sulphate, heparin or hyaluronan.
4.3. Studies on KS as a marker of cartilage catabolism in joint disease 
Quantitative and qualitative analyses of fragments of cartilage PG in blood and 
synovial fluid have provided important information on the catabolism of articular 
cartilage PG in a single synovial joint. The contention that most of the KS 
molecules in blood represent degradation products of cartilage PGs is supported 
by studies such as that of Block, Schnitzer, Andersson, Lenz, Jefferey, Me Neill 
and Thonar (1988), wherein papain-induced chemonucleolysis of an 
intervertebral disc resulted in a significant increase in the concentration of KS in 
serum, compared to patients who had undergone laminectomy. Similarly, in the 
study of Williams, Downey and Thonar (1988), papain-induced destruction of 
articular cartilage in a single joint in rabbits was accompanied by a 3 to 5 fold 
increase in the concentration of KS measured in serum, lasting 48 hours, before 
progressively decreasing to baseline values at nine days post-injection.
Levels of cartilage PG epitopes measured in synovial fluid reflect the 
metabolism/catabolism of PG within that joint. It can be argued that measurement 
of PG epitopes in blood represents the average of what is occurring in all 
cartilages in the body. However, the studies of Block and others (1988) and 
Williams and others (1988) discussed above suggest that extensive degradation of 
PG within a single joint can be detected by changes in serum PG concentrations.
Witter, Roughley, Webber, Roberts, Keystone and Poole (1987) demonstrated 
that synovial fluids collected from arthritic joints contained significant amounts 
of PG fragments of different sizes and composition. It was found that the 
synovial fluid from patients with reactive arthritis had much higher levels of PG 
epitope than that from patients with rheumatoid arthritis, leading Saxne, 
Heinegard and Wollheim (1986) to suggest that measurement of the levels of 
epitope in synovial fluid could be used diagnostically. These authors also showed 
that the levels of PG epitope decreased significantly over time following intra- 
articular injection of glucocorticoid. This lead to the suggestion that measurement 
of the level of PG epitope over time could be used to monitor the progress of the 
disease. Lohmander, Dahlberg, Ryd and Heinegard (1989), using the same assay 
also demonstrated that joint trauma caused the release of cartilage PG fragments 
into the synovial fluid, and suggested that in the acute phase after injury, synovial 
fluid levels of PG epitope could be related to the severity of the disease, but in 
the later stages, they may reflect the degree of chronic joint instability.
Studies by Lohmander and others (1989), showed that high synovial fluid 
concentrations of PGs were found in acute inflammatory conditions e.g. reactive 
arthritis, but that there was a broad range of lower concentrations in chronic
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conditions. However, as the chronicity of the latter conditions was not staged, 
there may have been a number of different subgroups within the range. Ratcliffe 
and others (1988) have shown that in the acute stages of joint disease, there is a 
rapid increase in PG concentration in synovial fluid, however, this is not 
sustained during non-active stages. In more chronic joint diseases, the 
concentrations of PGs in synovial fluid were lower than in acute disease and 
showed little apparent correlation with clinically assessed disease activity. The 
failure to detect greatly increased concentrations in most patients with chronic 
disease may be due to several factors, e.g. the activity involved in the rate of 
release of PG may be less than in acute disease. If there are episodes of rapid 
release in chronic disease, these may be of short duration or infrequent, or both, 
or may precede clinical signs, such that they do not coincide with clinical 
sampling. Finally, if only small changes occur, these may be masked by the 
broad range of natural variation in PG concentration that is evident in the patient 
population.
4.4. Use of KS as a marker of generalised cartilage catabolism 
Thonar and others (1985) demonstrated that patients with OA had significantly 
higher circulating levels of KS than patients hospitalised for conditions other than 
joint disease (control population). It has also been elucidated that a significant 
proportion of patients with OA do not have elevated levels of the KS epitope 
while a small percentage of adults without any clinical signs of OA do have 
elevated KS levels (Thonar and others 1991b).
Results of several studies, (Thonar, Schnitzer and Kuettner 1987; Sweet and 
others 1988) have shown that a single measurement of the concentration of serum 
KS is not very useful in the assessment of cartilage destruction in arthritic joints. 
The large range of serum KS in human patients hinders the usefulness of the KS 
assay as a diagnostic test for OA or its subsets (Thonar and others 1988a).
It is postulated that apparently normal individuals with significantly higher than 
average KS levels may be at risk of developing OA subsequently and that the 
persistent elevation of KS in these individuals for a prolonged period following 
joint injury may be indicative of a generalised disturbance in cartilage 
metabolism. This hypothesis has been compounded by the result of several 
studies (Sweet and others 1988; Brandt and Thonar 1989). In the study of Sweet 
and others (1988), patients with hypertrophic OA were shown to have 
significantly higher serum KS levels than adults without joint disease. These 
patients generally had multiple joint involvement. It was also noted that they had 
significantly elevated levels of KS six months following the removal of a 
degenerate joint (hip joint). This suggested that abnormal PG degradation in the 
degenerate hip joint was not a major influence on the high preoperative KS level 
and that a more generalised disorder of cartilage was present.
Additional support for the concept of a systemic or generalised increase in the 
rate of metabolism of cartilage PG in OA is found in the studies of Brandt and 
Thonar (1989), and Manicourt, Lenz and Thonar (1991). In experimentally
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induced canine OA, transection of the anterior cruciate ligament caused a rapid 
increase in serum concentration of KS which remained elevated until twelve 
weeks post surgery (Manicourt and others 1991). This study showed that the 
level of KS epitope had risen by day seven and remained elevated for at least 
thirteen weeks post-operatively. The level of KS epitope in the synovial fluid of 
the operated joint was several times higher than in serum and correlated with 
serum levels of the epitope. Sham operation was not accompanied by any change 
in the level of serum KS at any time after surgery. This finding suggested that a 
significant proportion of the KS bearing fragments appearing in the serum after 
transection of the anterior cruciate ligament are derived from an increase in the 
rate of catabolism of articular cartilage PG within the operated joint. However, 
the relationship of this elevation to the subsequent development of OA has not 
been frilly elucidated.
In the study of Brandt and Thonar (1989) similar results were obtained using the 
same model of joint disease. The PG content of the operated knee did not change 
during this time, suggesting that the increase in metabolic activitiy of the 
chondrocytes was restricted to the cartilage in the operated knee. However, the 
magnitude of the rise in serum KS suggested that it was more systemic or 
generalised in nature.
Measurement of the levels of serum KS epitope in models of OA such as the 
anterior cruciate ligament transection model have been suggested as a useful non- 
invasive tool for the study of the effects of chondroprotective agents and other 
drug treatments in the prevention of post-operative OA changes in this model 
(Pelletier and Martel-Pelletier 1989).
4.5 Studies on keratan sulphate as a marker of joint disease in the horse
There is a relative paucity of information on KS in the horse compared to human 
literature. Efforts in veterinary medicine have primarily been concentrated on the 
use of KS as a marker for OA and other forms of joint disease in the horse.
Previous investigators have studied GAGs in synovial fluid, serum and urine of 
both normal horses and those with various forms of joint disease. Little, Hilbert, 
Wickstrom and Hedlund (1990), found no difference in GAG levels in synovial 
fluid from horses with OA and normal horses, whereas Alwan, Carter, Bennet 
and Edwards (1990) reported high levels of GAGs in synovial fluid, serum and 
urine of horses with OA compared with normal horses. Levels of GAGs in horses 
with septic arthritis were lower than those reported in OA (Alwan and others
1990). In their study, high levels of GAGs were also found in infectious and 
traumatic arthritis and OA and therefore, could not be considered as a specific 
marker for OA. The limitations of measuring GAGs as indicators of articular 
cartilage pathology are highlighted also by the fact that they are synthesed by 
synovial tissue (Hammerman, Smith, Keiser and Craig 1982; Marsh, Wiebkin, 
Gale, Muir and Maini 1979) and therefore are neither restricted to PGs or 
specific for cartilage compared to KS.
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In another study, Alwan, Carter, Bennet, May and Edwards (1990), investigated 
articular cartilage breakdown using an ELISA for KS. They also measured 
sulphated GAGs (S-GAGs) using the dimethylene blue (DMB) assay of Famdale, 
Buttle and Barret (1986). The latter assay has the disadvantage of measuring all 
the released S-GAGs whether they are from cartilage or other tissues in the joint. 
This study demonstrated that a significant proportion of horses with OA had 
elevated levels of KS both in articular cartilage and serum compared to their 
group of normal horses. Serum levels of KS were found to be much lower than 
synovial fluid levels and there was no correlation with joint measurements. There 
was no correlation between the presence of neutrophils in synovial fluid and KS 
levels. A good correlation was found between synovial fluid measurements of S- 
GAGs and KS. However, as stated above, this does not imply that they are 
measuring identical pathological mechanisms. They concluded that synovial fluid 
KS measurements had potential for use as markers of degradation of cartilage in 
OA.
In a study by Yovich, Carroll and Bell (1991), KS concentrations in synovial 
fluid from the midcarpal joint of horses were measured using the modified 
(Carroll, Stuart, Armstrong, Breidahl and Laing 1991) DMB assay of Famdale 
and others (1986). The horses presented for lameness referrable to this joint were 
lame on trotting and had synovial effusion. Intra-articular anaesthesia of the 
affected joint relieved the lameness. Results of this study showed that in the 
group of lame horses, there was no difference in synovial fluid KS levels 
compared to normal horses.
Todhunter, Yeager, Freeman, Parente and Lust (1993) used KS as a marker of 
hyaline cartilage catabolism in the evaluation of the response of cartilage to 
surgically created focal osteochondral defects or generalised chemical destruction 
using chymopapain. They also evaluated the effects of post-operative exercise 
and intra-articular medication with polysulphated glycosaminoglycan (PSGAG) 
in this controlled study. Their findings indicated that there was a greater increase 
over baseline in KS measurements from synovial fluid and serum in 
chymopapain-injected joints (generalised cartilage destruction) compared to 
joints with focal osteochondral defects. In their study, the concentration of KS in 
synovial fluid was not related to the development of OA in ponies. Exercise or 
medication did not have an effect on plasma KS concentration and there was no 
correlation between synovial fluid and plasma KS concentration in any of the 
animal groups. The results of these experiments showed that KS concentration 
may be increased in acute, generalised marked articular cartilage catabolism and 
that the turnover of KS in cartilage with large osteochondral defects was affected 
by intra-articular medication with PSGAG. KS did not seem to be a definite 
marker of localised catabolism of aggregan as occurs in the later stages of OA. 
They concluded that changes in KS concentration may reflect generalised rather 
than focal hyaline cartilage catabolism.
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To date, studies in horses have concentrated primarily on the use of KS as a 
marker in the diagnosis of OA (Alwan and others 1990; Yovich and others 1991). 
The study by Todhunter and others (1993) is the first to critically evaluate KS as 
a marker of the effect of treatment and exercise in a model of equine joint 
disease. It has been shown in humans by Block and others (1989) that the level of 
serum KS does not fluctuate diumally or from day to day, however it has not 
been ascertained whether this is the case in the horse. In humans, it has been 
noted that moderate (Block and others 1989), or even strenuous exercise, as in 
running a marathon (Thonar and others 1991) did not result in significant 
changes in serum KS levels. Studies on synovial fluid GAGs in humans with 
joint disease have not included subjects in a daily vigorous exercise routine. The 
effect of exercise in racing/riding horses on the turnover or clearance of KS from 
synovial fluid or serum has not been examined. In studies carried out in both 
humans and animals, evaluating KS levels in joint disease, the contribution of 
age-related breakdown of articular cartilage in habitually unloaded regions that 
occurs in virtually every diarthrodal joint has not been taken into consideration 
(Brandt 1991). It is not known to what extent this may contribute to the serum 
concentration of a marker in normal and osteoarthritic subjects.
5. AIMS OF THE STUDY
The objectives of this project were as follows:
(1) To establish and validate an enzyme-linked immunosorbent assay (ELISA) 
for use in our laboratory to evaluate KS levels in equine synovial fluid and 
serum.
(2) To quantify KS levels in synovial fluid from carpal and tarsal joints and 
serum in a group of ’'normal" horses.
(3) To investigate whether there is (a) diurnal and (b) day to day variation in 
serum KS levels in normal ponies.
(4) To assess if serum KS levels in a group of racehorses in training are affected 
by a period of acute exercise.
(5) To monitor synovial fluid KS levels in three cases of degenerative joint 
disease and to evaluate longitudinal measurements of serum KS in these animals 
post-operatively / in the recovery phase.
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CH APTER II
GENERAL METHODS
1. PURIFICATION OF PROTEOGLYCAN A1D1 MONOMER BY 
DENSITY GRADIENT CENTRIFUGATION
Cartilage PG may be extracted either by a disruptive procedure with high speed 
homogenisation of the tissue or a dissociative procedure, involving extraction 
with a high-ionic strength salt solution (Hascall and Sadjera 1969).
The latter technique is favourable as it minimises enzymatic and mechanical 
fragmentation of the macromolecules (Dunstone and Cleland 1975). This method 
of extraction releases 80 per cent of the tissue PGs, which contain 87 per cent 
CS, 6 per cent KS and 7 per cent protein (Hascall and Sadjera 1969). Subsequent 
fractionation of the extract using density gradient centrifugation allows the 
isolation of approximately 95 per cent of the extracted PG as PG subunit.
1.1 Principles of associative and dissociative density gradient centrifugation 
Extraction of PG with 4 M guanidine hydrochloride (GHC1) results in a solution 
that contains both aggregated and non-aggregated molecules (Hardingham and 
Muir 1974). In the study of Hardingham and Muir (1974), dissociation of 
purified PG aggregates was shown to release an interacting component of 
buoyant density higher than that of the glycoprotein-link fraction of Hascall and 
Sadjera (1969). Equilibrium density gradient centrifugation of the purified PG 
from bovine nasal septum cartilage in the presence of 4 M GHC1 was shown to 
dissociate aggregates and separate a protein-rich fraction from the majority of the 
PG (Hascall and Sadjera 1969). This protein-rich fraction contained hyaluronan. 
Most of the hyaluronan in cartilage is associated with PG aggregates 
(Hardingham and Muir 1974).
Purification of PG monomer from bovine nasal cartilage is carried out in a two 
stage process. First, tissue slices are extracted with 4 M GHC1. The caesium 
chloride is added directly to the clarified extract and an equilibrium density 
gradient is established in an associative gradient. The associative step is carried 
out first to purify PG and hyaluronan.
Fractionation in an associative gradient results in a fraction, A1 (Figure 4), that 
contains PG and hyaluronan, and a fraction, A2, that contains collagen and is 
protein-rich. This is followed with a dissociative procedure to obtain PG 
monomer. Fractionation in a dissociative gradient separates non-covalently bound 
protein from purified PG. The fraction D1 will contain hyaluronan and non- 
covalently bound protein and the fraction D2 will contain disaggregated PG 
(Figure 4). All procedures are carried out in the presence of protease inhibitors to 
ensure that intact PG monomer is obtained.
II
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Figure 4
Principle of associative and dissociative density gradient centrifugation.
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1.2. Materials and methods
All chemicals used were analytical grade. Suppliers of reagents are listed in 
Appendix 1. Details of the composition of buffers used at the various stages are 
contained in Appendix 2.
Bovine nasal septum cartilage (6.6 g wet weight) was obtained from a two year 
old animal within 30 mins of death and placed in a Tris buffer (Trizma base, 
0.05M, sodium chloride 0.15M, sodium azide (w/v) 0.01 per cent, ethylene 
diamine tetraacetic acid (EDTA) 0.01M, pH 4.3) kept at 4 °C until processing. 
The cartilage was processed within three hours of collection.
The cartilage was cut into small pieces and homogenised using a Thyristor Regler 
homogeniser. Proteoglycans were extracted for 65 hours at 4 °C with constant 
stirring in 100 ml solution of sodium acetate buffer (0.05M sodium acetate 
trihydrate pH 5.8 (Hascall and Sadjera 1969) with protease inhibitors (EDTA 
0.1M, 6-aminocaproic acid 0.1M and benzamidine 0.005M (Oegema, Hascall 
and Dziewiatkowski 1975  ^containing 4M GHC1.
Prior to associative density gradient centrifugation (ADGC) the homogenised 
tissue solution was centrifuged at 2054 g  for 15 minutes at 4 °C and the 
supernatant was added to seven times the volume of sodium acetate buffer to 
make up a final concentration of 0.5 M solution of GHC1.
1.3. Associative density gradient centrifugation
The extract in 0.5M GHC1 was adjusted to a starting density of 1.69 g/ml. with 
solid caesium chloride. 1.19 g of solid caesium chloride per gram of supemate 
was added (Patel 1981) The theoretical gradient for the rotor was calculated 
using the method of Ifft, Voet and Vinograd (1961), (Appendix 3) and was 
between 1.51 g/ml (p min.) and 1.85 g/ml (p max). The extract was placed in 11 
ml polypropylene tubes (Beckman Ltd. U.K) with metal-rubber expander caps. 
The tubes were centrifuged at 147,500 g  at 18 °C in a Beckman ultracentrifuge 
angle rotor (Ti60) for 48 hours. The rotor was allowed to come to rest with the 
brake off to avoid any vibration disturbing the gradient.
1.4. Fractionation of gradients
Fractionation was carried out using a tube piercer (MSE U.K.). Fractions of 
approximately 1.1 ml each were collected in 1.5 ml Treff tubes (Scotlabs. U.K.). 
The densities of the isopycnic gradient profiles created at 48 hrs under ADGC 
conditions were measured using a density meter (Paar Scientific Ltd.) and are 
shown in Table 2. Only fractions with a starting density greater than 1.72 g/ml 
were included (Hascall and Sadjera 1969; Patel 1981). This consisted of the 
bottom four fractions from each tube. Approximately 95 per cent of the extracted 
PGs are present at a density greater than 1.72 g/ml, (Hascall and Sadjera 1969). 
The total volume of solution recovered at this stage was 44 ml.
32
1.5. Dissociative density gradient centrifugation
Fractions of starting density greater than 1.72 g/ml were pooled and converted to 
dissociative conditions by adding an equal volume of 7.5M GHC1. Caesium 
chloride was added empirically to the PG preparation in 4M GHC1 to adjust the 
starting density to 1.52 g/ml (gradient formed during centrifugation, p  min 1.33, p  
max 1.65) (Appendix 3). The tubes were centrifuged in the same rotors under the 
same conditions as above. Following ultracentrifugation, the tubes were taken 
and fractionated as before. The density of each fraction was estimated using a 
density meter as above, and the bottom four fractions from each tube were pooled 
(density greater than or equal to 1.54 g/ml). The recovery volume was 17.6 ml. 
Densities of the fractions obtained are shown in Table 3.
The PG solution (8.8ml) was then dialysed (Dialysis membrane, Pierce U.K. 
Ltd.) initially for 24 hours against sodium acetate buffer and then for 24 hrs 
against distilled water to remove impurities and salts. The dialysate was 
lyophylised in plastic graduated Henley tubes (Sarstedt U.K. Ltd.) for 48 hours. 
The weight of PG monomer recovered was 9.2 mg.
1.6. Results
The density gradients for the associative density gradient centrifugation (ADGC) 
and dissociative density gradient centrifugation (DDGC) are shown in Figures 5 
and 6. They matched well the predicted values calculated from the theoretical 
gradients. Differences between the actual and theoretical gradients can be 
explained by the fact that the theoretical gradient is calculated using a pure 
caesium chloride solution. In the actual density gradient, the densities measured 
come from a solution which contains GHC1 and protein material which 
contribute to the variation from the calculated gradient.
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Fraction Tube 1 Tube 2 Tube 3. Mean.
10 1.81 1.78 1.80 1.79
9 **♦ 1.78 1.79 1.79
8 1.74 1.76 1.76 1.76
7 1.73 1.74 1.74 1.74
6 1.71 1.72 1.72 1.72
5 1.69 1.67 1.69 1.69
4 1.68 1.67 1.67 1.67
3 1.66 1.65 1.65 1.65
2 1.64 1.63 1.63 1.63
1 1.62 1.62 1.62 1.62
***= fraction lost.
Table 2
Densities of fractions obtained from associative density gradient centrifugation.
Individual values of each of the ten fractions from three randomly selected tubes and mean values 
of each fraction from the three tubes are shown. Densities were measured (g/ml) using a digital 
density meter (Paar Scientific Ltd.)
Fraction Tube 1 Tube 2 Tube 3 Tube 4 Mean.
10 1.59 1.59 1.61 1.62 1.60
9 1.57 1.58 1.59 1.58 1.58
8 1.55 1.57 1.56 1.57 1.56
7 1.53 1.54 1.54 1.54 1.54
6 1.51
5 1.48
4 1.45
3 1.43
2 1.41
Table 3
Densities of fractions obtained from dissociative density gradient centrifugation.
Four tubes were fractionated; of these one tube had every fraction measured. The mean values of 
the bottom four fractions are also recorded. Densities were measured (g/ml) using a digital 
density meter (Paar Scientific Ltd.).
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2. PLATE COATING PROCEDURE
2.1. Materials
Bovine Nasal Septum A1D1 (BNS/ A1D1), the antigen used to coat plates was 
stored, dessicated at —20 °C. Prior to weighing, the purified PG was thoroughly 
dried, by lyophylisation for 24 hrs. The same procedure was followed every time 
BNS/A1D1 was used to ensure uniformity in plate coating.
2.2. Plate coating
Nunc Immuno Plates (A/S Nunc, Denmark) were cleaned by immersing in a 50 
per cent ethanol, 50 per cent distilled water solution for 20 mins. The plates were 
emptied and dried thoroughly.
The chondroitin ABC lyase (ICN Biomedicals Ltd., U.K) was reconstituted by 
adding 1 ml of chondroitin ABC lyase buffer (0.1M sodium acetate, 0.1M Tris, 
pH 7.3) (Appendix 4) to 5 units of enzyme. A quantity of 4.8 mg of dried BNS- 
A1D1 was weighed out, sufficient for 40 plates. The reconstituted chondroitin 
ABC-lyase was subsequently added to the BNS/A1D1 in the ratio of 0.2 units of 
chondroitin ABC lyase to 1 mg of BNS/A1D1. The tube was capped and 
incubated at 37 °C with shaking for 2 hours.
The chondroitin ABC-lyase treated BNS/A1D1 was carefully diluted with 
prepared coating buffer in the ratio of 1ml of chondroitin ABC lyase to 800 ml of 
plate coating buffer (20 mM sodium carbonate, 20 mM sodium bicarbonate, 
0.002 per cent sodium azide, pH 9.2) (Appendix 4). The tube was repeatedly 
rinsed with buffer. Only enough of the coating buffer as would coat several 
plates in a reservoir was poured out. The remainder was left in a glass beaker 
with constant stirring.
Using the multi-channel pipette (Titertek plus, ICN Biomedicals U.K.), 200 pi of 
the coating material was added to all wells of one plate and the plate was covered 
using plate sealer (ICN Biomedicals Ltd. U.K.) labelled accordingly. After 
incubating plates for 2 hours at room temperature, the coated plates were stored 
at 4 °C overnight or until needed. Plates can be stored for up to 6 months 
(Thonar, unpubl.). The plate sealer material was checked periodically to ensure it 
was airtight and to prevent evaporation of the coating buffer from individual 
wells.
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3. DETERMINATION OF THE TITRES OF ANTIBODIES REQUIRED 
TO OPTIMISE THE KERATAN SULPHATE ASSAY
3.1. Principle
In order to optimise assay conditions, it was necessary to determine the strength 
or titre of both antibody preparations used in this assay. A simple direct enzyme- 
linked immunosorbent assay (ELISA) was used. The principle of this test is that 
the first antibody will bind to KS antigen adsorbed on the microtitre plate, 
thereby binding some antibody to the plate. Then, following washing of the plate, 
a second antibody is added, which is covalently bound to peroxidase, directed 
against the first antibody. The amount of second antibody bound to the plate is 
quantified by monitoring the amount of coloured end product formed during final 
incubation of the substrate for peroxidase.
The objective of the checkerboard design was to test both variables (first and 
second antibodies) in order to find a point at which both would give the optimum 
O.D., i.e. between 1.5 and 1.8 absorbance units. The optimum concentration of 
monoclonal anti-KS antibody (first antibody) was chosen by selecting the second 
antibody concentration that gave a steep inhibition curve and a near maximum 
colour development (1.8 absorbance units) after 15 to 30 mins. At that 
concentration of second antibody, the concentration of first antibody that gave 
near maximum colour development (i.e. 1.5 to 1.8 absorbance units) was 
selected.
3.2. Assay method
The anti-KS monoclonal antibody (1/20/5D4, ICN Biomedicals U.K. Ltd.) (first 
antibody) was prepared as a 1/100 dilution in PBS Tween 20 (sodium chloride 
120 mM, disodium hydrogen orthophosphate 5 mM, EDTA 10 mM, Trizma base, 
0.5ml, pH 7.0). (Appendix 5).
The first antibody (1/100 dilution) was made up to a 1/1000 dilution in PBS 
Tween 20, 1 per cent bovine serum albumin (BSA), pH 5.3(andbody buffer) 
(Appendix 9). The serial half dilutions were prepared in a microtitre plate 
(transfer plate), (A/S Nunc Denmark), by adding 280 pi of the first dilution, 
(1/1,000), to the first well and adding 140 pi of antibody buffer to the remaining 
wells. The first dilution was then serially half diluted. The plate was mixed with 
shaking for 1 hour at room temperature.
Following mixing, 200 pi of this antibody dilution was transferred to a washed 
plate, coated with KS antigen and incubated with shaking for an hour at room 
temperature. The enzyme-labelled antibody (sheep anti-mouse IgG horseradish 
peroxidase, SAM-HRP, SAPU Ltd. U.K.) (second antibody) titre was determined 
in the same plate by by testing a narrower concentration range, (i.e. 1/50 to 
1/200) of the second antibody (Appendix 6).
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3.3. Determination of the titre of first antibody, all other variables known
As it was necessary to acquire a new batch of first antibody during the course of 
the ELISA work, the optimum concentration of the new batch of monoclonal 
antibody had to be determined to satisfy the assay requirements.
3.4. Methods
140 pi of PBS-Tween 20, pH 5.3, (instead of sample containing an unknown 
amount of KS) and 140 pi of first antibody (1/1,000 starting dilution) were added 
to two wells of a transfer plate. A serial half dilution of this ’’first” dilution was 
carried out to a final dilution of 1/128,000 (Appendix 7). The first antibody was 
pre-incubated for one hour to mimic the actual assay conditions. This mixture 
contained zero concentration of KS and 140 pi of MAb. The rest of the ELISA 
was carried out as described above to determine the concentration of MAb 
required to give an OD between 1.5 and 1.8 at 490 nm.
4. STANDARDISING THE KS ASSAY.
4.1. Materials and methods
International reference standards (IRS) of purified costal cartilage KS were a gift 
from Dr. A.L. Horwitz, University of Chicago. The IRS contained 411 ng/ml of 
pure KS. It was necessary to determine the concentration of KS equivalents in 
our working standard (WS) material, purified at Glasgow Royal Infirmary. The 
WS was prepared for estimation of its concentration of KS equivalents by making 
a 1/67 dilution with distilled deionised water containing 0.05 per cent Tween 20 
(total volume 25 ml). This was known as WS stock solution. By a process of trial 
and error, an initial starting dilution of the WS stock solution of 1/25 was chosen. 
The ELISA assay with an inhibition step was carried out as described earlier and 
each sample of WS was assayed in duplicate. The results of standardisation of 
the WS are shown in Table 4.
Starting dilution of Result (ng/ml of KS equivalents)
working standard
1/25 436
1/25 428
1/25 439
1/25 430
1/25 426
1/25 431
Mean value 432 ng/ml
SD ± 4.9
Table 4
Standardisation of the working standard stock (WS) solution. 
Results are expressed as ng/ml of KS equivalents.
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5. TECHNIQUE OF THE KS ELISA 
(INCORPORATING AN INHIBITION STEP)
5 .1 . Principle of the ELISA technique
Enzyme-linked immunosorbent assays are based on the sandwich technique and 
have been used widely to determine titres and specificity of antisera as well as to 
measure antigens both qualititively and quantitatively. The KS ELISA described 
below incorporates an inhibition step, i.e. the unknown sample and the first 
antibody, (1/20/5D4), are incubated together for a period of one hour prior to the 
addition of the specific antibody to the coated plates. The incorporation of an 
inhibition step allows the quantitation of antigen present in the unknown samples 
(Rennard, Kimata, Dusemund, Barrach, Wilczek, Kimura and Hascall 1981).
Following the inhibition step, the competitive indirect ELISA is carried out, using 
the method of Thonar and others (1985) with minor modifications (Thonar and 
others 1991). The ELISA is represented in diagramatic form in Figure 7. The 
inhibition mixture, consisting of unknown antigen and first antibody is 
transferred to washed plates, coated with KS antigen. Any unbound first antibody 
will bind to coated KS antigen on the plate. After the end of the incubation 
period, the plate is washed three times. The plate is washed between incubations 
to remove any antibodies not specifically bound.
A second antibody, SAM-HRP is added. The first and second antibodies are 
made up in solutions of pH 5.3 (Thonar and others 1991b). This facilitates the 
quantification of KS, as ELISAs carried out at this pH yield steeper inhibition 
curves for both standards and unknowns, thereby increasing the ability to 
discriminate between concentrations of antigen that are not markedly different. 
The lower pH also helps to reduce non-specific binding. The plate is washed 
again following incubation.
The amount of second antibody bound to the plate is quantitated by monitoring 
the amount of coloured end product formed during the final incubation with 
substrate for the peroxidase. The concentration of KS antigen present in the 
unknown sample is calculated by comparing the absorbance value in each case to 
values generated from known concentrations of highly purified human costal 
cartilage KS antigen equivalents, used as WS in the assay.
The intensity of the colour reaction is inversely proportional to the amount of 
antigenic KS in the sample. The WS is treated in an identical manner to the 
unknown samples and is incorporated in the same plate. All concentrations of 
synovial fluid and serum KS reported in this study represent equivalents of this 
WS. Half-inhibition binding of the antibody to the coated antigen occurs when 
the antigen is present at a concentration equivalent to 5 ng of WS per ml of 
solution tested. Complete inhibition (>95 per cent) was reached at a 
concentration of 15 ng per ml. This is defined as the working range of the assay 
under the conditions described below.
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Figure 7
Principle of the KS ELISA incorporating an inhibition step
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5.2. Collection and processing of samples
Blood samples (7 to 10 ml) were collected aseptically by jugular venepuncture 
into vacutainer tubes containing no anticoagulant. Synovial fluid samples were 
aspirated aseptically (without opening the joints in normal animals in Experiment 
1) using a 19 gauge 1 V2 inch needle and syringe. All samples were stored at 4 °C 
until processing within three hours of collection. Both synovial fluid and blood 
samples were centrifuged at 4 °C at 2054 g  for 10 mins. Serum was separated 
and stored at —20 °C in 1.5 ml TrefF tubes (Scotlabs. U.K.) The synovial fluid 
aspirate was stored under the same conditions following centrifugation. All 
synovial fluid and serum samples were identified according to the Joint Naming 
Code (Appendix 8).
5.3. Inhibition step
Details of the composition of buffers used in the assay are contained in 
Appendices 5 and 9. The WS and the unknown serum and synovial fluid samples 
were diluted in working buffer in 3 ml polypropylene tubes (Sarstedt UK).The 
working standards were diluted 1/4 as the starting dilution. They were stored at 
—20 °C until required and once in use, were stored at 4 °C for 2 to 3 days.
The "unknown” equine serum and synovial fluid samples were stored at —20 °C 
and once thawed, were stored at 4 °C until used. Prior to dilution, all samples 
were mixed thoroughly (Maxi-Mix 1, Radley’s Lab. Equipt. U.K.) for 10 
seconds. Once diluted in working buffer, all samples were mixed thoroughly 
again for 10 seconds immediately prior to pipetting. In general, serum was 
diluted either one in five or one in ten with working buffer as the starting 
dilution, and synovial fluid was usually diluted 1/100 or 1/200 as the starting 
dilution.
Using the plate template as a guide, 280 pi of each first dilution sample and 
standard was pipetted into the appropriate well. A multichannel pipette (Titertek 
Plus, ICN Biomedicals Ltd. U.K.) was used to add 140 pi of working buffer to 
all remaining wells. Using the multichannel pipette, serial half dilutions were 
performed. All wells finally contained 140 pi of sample and PBS.
The appropriate concentration of first antibody was diluted in antibody buffer. 
The concentration of anti-KS monoclonal antibody used varied from one batch of 
plates to another, depending on the half-inhibition value of the batch. (The first 
two batches of plates required a concentration of 1/30,000 MAb. The third batch 
of plates required a MAb concentration of 1/25,000). Following thorough mixing, 
and using the multichannel pipette, 140 pi of the MAb dilution was pipetted into 
each well of the microtitre plate. The plate was incubated with shaking on the 
Varishaker for 1 hr at 25 °C and the ELISA carried out, or the plate was covered 
with a plate sealer (ICN Biomedicals Ltd. U.K.) and stored until the next day for 
assay.
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5.4. The ELISA technique
The inhibition mixture of first antibody with either standard or sample was 
incubated in coated plates. After washing, an enzyme-labelled antibody (second 
antibody) directed against the first antibody was pipetted. Finally the substrate 
for the enzyme was added and colour development occurred.
The coated plates, (stored at 4 °C) were allowed to come to room temperature (if 
left overnight). The coating buffer was removed from the plate and three five 
minute washes with working buffer were carried out. Using the multichannel 
pipette, 200 pi of the inhibition mixture in the transfer plate was transferred to 
the washed coated plate using fresh pipette tips for each row of wells. The coated 
plate was covered and incubated for 1 hr at room temperature with shaking.
Following incubation, the inhibition mixture was discarded and plates were 
washed again three times using working buffer. Ten minutes prior to use, the 
second antibody was prepared in antibody buffer at the appropriate dilution, e.g. 
1/125. Using the multichannel pipette with clean tips, 200 pi of diluted SAM- 
HRP was pipetted into the washed coated plate, covered with a plastic plate lid 
and incubated at room temperature with shaking for 1 hr.
After 45 mins. of incubation of the coated plate with the second antibody, the 
substrate for the colour reaction was prepared and tested. O-phenylene diamine 
(OPD) colour reagent was prepared (25 ml of 0.05M citric acid, 0.10M disodium 
hydrogen orthophosphate, 10 mg of OPD, 11 pi of hydrogen peroxide, 30 per 
cent w/v, Appendix 9). The second antibody was removed from the coated plate 
and three five minute washes were carried out with working buffer. Using the 
multichannel pipette with clean tips, 200 pi of prepared substrate was added to 
the washed coated plate and the colour development carefully monitored over the 
ensuing 15 to 30 min. period (Figure 8).
The plate was read at approximately 4 min intervals on a microplate photometer 
(Dynatech Laboratories Ltd., U.K.) at 490 nm until the optimum assay conditions 
had been reached, i.e. the standards gave an O.D. reading between 1.5 and 1.8 at 
490 nm. The half inhibition of the standard curve of the colour reaction occurred 
when the antigen was present at a concentration equivalent to 5 ng of working 
standard KS per ml of solution to be tested (Figure 9). Complete inhibition (> 95 
per cent) occurred at a concentration of 15 ng per ml.
The calculation of the amount of KS equivalents in the ’’unknown” samples was 
derived using Dynatech software (Dynatech MR 5000, Dynatech Labs. Ltd., 
UK). Only values which fitted on the linear portion of the semi-log curve were 
accepted. Values of the unknown samples were calculated from the average of 
the absorbances obtained on duplicate samples which were referenced against the 
WS incorporated into each plate. Values fitting on the linear portion of the 
I standard curve between a 30 per cent to 60 per cent inhibition window were
accepted. If more than one value from the same sample fitted on the curve then
! \
I
j
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the values were averaged and this figure taken to represent the true value 
measured. Where either serum or synovial fluid dilutions were inappropriate such 
that no values fitted on the curve, the starting dilution was adjusted and the 
sample repeated.
Figure 8. Colour development in the keratan sulphate ELISA.
The intensity o f the colour reaction is inversely proportional to the amount o f keratan sulphate in 
the sample.
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6. PROCEDURES FOR VALIDATION OF THE KS ELISA
6.1. Intra-assay Coefficient of Variation
An intra-assay coefficient of variation (C.V.) test was carried out using serum at 
a starting dilution of 1/10 in working buffer (Appendix 10). Each serum sample 
was serially half-diluted from a starting dilution of 1/10. The plate template was 
designed as in Appendix 10. The ELISA with an inhibition step was carried out 
under identical conditions as with a routine assay. The values obtained from the 
test are shown in Table 5. The intra-assay C.V. was calculated at 4.3%.
6.2. Interassay Coefficient of Variation
An interassay C.V. was established for each batch of plates. A quality control 
serum sample was incorporated into each plate. A paired t-test was carried out on 
the values obtained with the quality control serum included in each plate and 
assayed in each batch. The inter-assay C.V.on the first batch of plates was 11.5 
per cent, the second batch of plates had an inter-assay C.V. of 10.5 per cent and 
the third was 10.9 per cent (Table 6). The first two batches of plates required a 
first antibody concentration of 1/30,000 and the third batch of plates required a 
first antibody concentration of 1/25,000. Plates giving results within the 
percentage range calculated on the batch of plates being used were accepted as 
valid. Results outwith this percentage range were excluded.
6.3. Effect of storage on samples
A serum sample, initially diluted one in five with working buffer was stored at 
—20 °C, 4 °C and at room temperature to evaluate the effect, if any, of different 
storage conditions on the stability of the antigenic KS epitopes in the samples. 
Prior to storage over an eight week period, the concentration of KS was 
estimated. The samples were stored for this length of time as all serum and 
synovial fluid samples collected were assayed for KS within two months of 
collection and processing for storage. The results of this experiment are shown in 
Table 7.
6.4. Spiking the assay
In order to test the accuracy of the assay, and the possibility of interference, i.e. 
blocking factors in serum, a serum sample containing a known amount of KS 
(previously assayed twice consecutively) was spiked with known concentrations 
of WS.
The WS contains 433 ng/ml of purified KS. The serum sample contained 118 
ng/ml of KS equivalents. A 1/5 starting dilution of the serum sample without a 
spike in working buffer was incorporated into the plate. The first spike contained 
54 ng/ml of WS. 125 pi of WS containing 54 ng/ml was added to 100 pi of 1/5 
diluted serum. A second spike was prepared to contain 108 ng/ml of WS. 125 pi 
of this 1/4 dilution was added to 100 pi of 1/5 diluted serum. Samples were 
prepared and assayed in duplicate using the competitive indirect ELISA with an 
inhibition step as described above.
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From the results of the spike assay, (Table 8) it can be seen that there was a 
linear increase in response on addition of exogenous KS to serum of known KS 
concentration. The first spike of 54 ng/ml of WS gave a reading that was 15 per 
cent above the predicted value. This was outwith the 10.9 per cent interassay 
C.V.
The second spike of 108 ng/ml gave a reading 35 per cent greater than the 
predicted value. This was higher than the 10.9 per cent variation allowed on the 
interassay C.V. Although this reading was high, it showed that there were no 
blocking factors reducing the measurement of KS in equine serum, a finding that 
agreed with the work of Seibel, Towbin, Braun, Kiefer, Muller and Paullsen 
(1989) using the ELISA assay on human serum.
Well No. KS equivalents.
3 and 4 578, 536
5 and 6 571, 522
7 and 8 542, 585
9 and 10 522, 574
11 and 12 572, 531
Mean ± S.D. 554 ± 24
Intra-assay C.V. 4.3%
Table 5
Intra-assay coefficient of variation (C.V.)
The quality control (QCS) serum values are expressed as ng/ml of KS equivalents. The QC 
serum was diluted 1/10 as a starting dilution in working buffer and serially half-diluted 
subsequently. The C.V. is calculated as SD divided by the mean value.
Plate 
Batch no. Mean Median S.D. S.E.M. C.V. N
1 523.4 521 60.7 21.5 11.5% 8
2 523.6 514 55.2 13.4 10.5% 17
3 460.4 441 50.3 15.2 10.9% 11
Table 6
Inter-assay coefficient of variation.
S.D.= standard deviation, S.E.M.= standard error of the mean, C.V.= coefficient of variation, 
calculated as S.D.divided by the mean. Quality control serum (QCS) was incorporated in each 
plate assayed. The QCS values are expressed as ng/ml of KS equivalents.
Storage conditions KS equivalent value.
Original sample 162
Minus 20 °C 118
Room Temperature ***
4°C 67.7
Table 7
Effect of storage (8 weeks) on the measurement of KS in serum.
All results are expressed as KS equivalents in ng/ml.
***= sample deteriorated and contaminated with fungal growth, thus, no value obtained.
Sample Calculated
Result
Actual
Result
%
of calculated 
result
serum x 118
x + spike 1 172 197 115
x + spike 2 226 306 135
Table 8
Spiking the ELISA with working standard (WS).
KS results are expressed as ng/ml.
Total volume of sample x plus spike= 500ul
Both spike samples are added to 1/5 starting dilutions of serum x.
Percentage values are expressed as absolute values.
Spike 1 = 54.1 ng/ml ofWS (1/4 diln.)
Spike 2 = 108 ng/ml of WS (1/8 diln.)
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6.5 Curve fitting procedures
In order to ascertain if the standard curve and the equine sample curves were 
parallel, the optical density values for six randomly selected equine serum 
samples were plotted against their dilution values (represented as a negative log 
scale) (Figure 10). From graphical evidence, the equine serum samples did not 
appear to be parallel to die standard curve. This suggested that there was an 
unknown factor/factors in equine serum which interfered with the assay in terms 
of the OD reading obtained.
The equine serum sample curves shown in Figure 10 were modelled using the 
approach of De Lean, Munson and Rodbard (1979). There was strong statistical 
evidence of difference in slope between the standard curve and some of the 
samples. When e.g., Horse 1 was compared with the Standard curve, the t 
statistic for comparing the slope parameters was 3.92 with 6 degrees of freedom 
(p =0.008). However, in terms of estimating the difference in log concentration 
between the standard and the sample, it made little difference in this instance 
whether parallel or non-parallel lines were fitted to the data (0.7, standard error
0.12, versus 0.78 with a standard error of 0.05 for parallel and non-parallel lines 
respectively (G Murray, personal communication).
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6.6. Cross Laboratory Quality Control
As part of a quality control exercise, four samples, serum and synovial fluid, 
human and equine) were assayed in two consecutive assays at Glasgow Royal 
Infirmary (GRI). The same samples were analysed at Rush-Presbyterian-St. 
Lukes Medical Centre, (RP) Chicago, under similar laboratory conditions using 
the same assay for KS. The interassay C.V. at GRI was 10.9 per cent. The 
interassay C.V. at RP was 11 per cent (Thonar, 1993 unpublished).
The mean value (calculated from two consecutive measurements on each sample, 
assayed in duplicate) is shown in Table 9. The absolute difference and 
percentage difference between samples is shown. The percentage difference is 
taken as the percentage change in the value obtained at RP as compared to GRI 
(taken as 100 per cent). Results were analysed using Students paired t-test, a 
level of significance p<0.05, 95 per cent confidence interval [Cl]. Although the 
sample numbers are small, (n=4), there was no significant difference in the 
results obtained in both laboratories.
Sample GRI RP Difference (abs.) 
value and % 
value
ESE 523 545 22 104 %
ESF 6588 4642 1946 70%
HSF 23687 24190 503 102 %
HSE 387 474 87 122 %
Table 9
Quality control on samples assayed in two different laboratories
ESF= equine synovial fluid, ESE = equine serum. HSF= Human synovial fluid, HSE= Human 
serum. GRI= Glasgow Royal Infirmary, RP= Rush Presbyterian.
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CHAPTER III
STUDIES IN NORMAL HORSES
1. EXPERIMENT 1. OBJECTIVES
The objective in evaluating KS levels in the joints sampled in a group of 
’’normal" horses was to obtain a range of values for the individual joints in order 
to assess:
(A) If there was any difference in values obtained from right and left paired joints 
between animals.
(B) If there was any correlation between serum and joint levels between animals.
In the group of animals sampled, it was decided to compare joints as follows: 
Paired, (i.e. right and left) radiocarpal joints were compared between animals. 
Paired midcarpal joints were compared between animals. Left radiocarpal and 
midcarpal joints were compared with right radiocarpal and midcarpal joints 
between animals.
Each of the carpal joints sampled was compared with the tibiotarsal joint on the 
corresponding side i.e. right radiocarpal compared to right tibiotarsal joint 
between animals and right midcarpal compared to right tibiotarsal joint between 
animals. The same procedure was carried out for left-sided joints. Serum KS 
values were compared with joint values (all joints) to assess if there was any 
correlation between serum and synovial fluid KS levels.
2. SUBJECTS, SAMPLES AND METHODS
KS levels were evaluated in a group of "normal" horses, i.e. defined within the 
context of the current study as animals that had no evidence of or history of joint 
disease, that were euthanased for other reasons (Appendix 11). The horses ranged 
in age from 2 years old to 15 years old. Seven horses were Thoroughbred or 
Thorougbred-cross, two were Clydesdales and two were ponies. Seven geldings 
and four mares were used. All animals had no evidence of articular cartilage 
pathology on visual inspection at at post-mortem examination.
Serum samples were collected by jugular venepuncture (7 to 10 ml), prior to death 
in most cases. Synovial fluid was collected immediately post-euthanasia by 
needle aspiration, using a 19 gauge 1 Vz inch needle and syringe without opening 
the joint. Subsequent to needle aspiration, each joint was opened and the articular 
cartilage visually inspected. Synovial fluid collected was processed (within one 
hour) as described on page 42 and stored at —20 °C until assayed.
2.1. Sites for synovial fluid aspiration
Synovial fluid was aspirated from the radiocarpal joint and from the midcarpal 
! joint (Figure 12). The latter joint communicates with the carpometacarpal joint.
I
i
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With the carpus flexed, the radiocarpal joint was located and the sample 
collected from a site midway between the medial edge of the radius and the 
proximal edge of the radial carpal bone.The needle was inserted at this site, 
medial to the medial edge of the extensor carpi radialis tendon. The volume of 
synovial fluid recovered was on average, 3 to 8 ml.
The midcarpal joint was located and the needle inserted medial to the extensor 
carpi radialis tendon. The average volume of fluid collected was 3 to 6 ml.
The tibiotarsal joint (Figure 11) was penetrated on the medial side of the 
saphenous vein as it traverses the joint vertically, approximately 2 to 3 cm below 
the level of the medial malleolus at the distal end of the tibia. The average 
volume collected was 5 ml.
The synovial fluid collected was assessed visually for any abnormalities, e.g. 
colour change or presence of debris. In all cases, synovial fluid appearance 
corresponded to what has been described as normal (Mcllwraith 1987).
2.2. Statistical methods
Results were analysed throughout this thesis using the Minitab Release 9 
statistical package (Appendix 1). The values for each joint in all animals and the 
corresponding serum values are contained in Appendix 12.
There was a wide range of values for each joint in the group of animals studied 
(Table 11 and Appendix 11). The values were checked and did not appear to be 
normally distributed. Due to the non-parametric nature of these values, ratios for 
paired values, rather than absolute values were used to normalise the data for 
statistical analysis.
Ratios were calculated for paired joints, e.g. BR/BL in all animals. The mean 
ratio across animals was then calculated. The ratios were plotted as histograms 
and found to be approximately normally distributed. Students t-test was then used 
on the mean ratios to test the null hypothesis that the mean ratio was equal to 
one, versus the alternative hypothesis that the mean ratio was not equal to one.
A level of significance, p <0.05 was used. The values for the paired joint ratios 
95% confidence interval [Cl], and significance levels are shown in Table 10. The 
median and range of synovial fluid KS values and serum values are shown in 
Tables 11 and 12 respectively.
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Figure 11
Plantaromedial view of 
the tarsus.
(a) Site of sampling 
the tibiotarsal joint.
Figure 12 
Dorsal view of the 
flexed carpus.
(a) Site o f sampling from 
the radiocarpal joint.
(b) Site o f sampling 
from the midcarpal 
joint.
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2.3. Results
Paired joint analysis (Table 10)
The individual joint values are represented for each animal as well as the median 
value for each joint in all 11 horses in Figures 13 to 18.
There was no significant difference in right and left radiocarpal joints between 
the 11 animals. There was no significant difference in right and left midcarpal 
joints between the 11 animals. Right and left tibiotarsal joints were compared 
between animals, (n=ll). Again, there was no significant difference in the values 
obtained.
The mean values obtained for the left carpal joints, i.e. the sum of the left 
radiocarpal and left midcarpal joints was compared to the sum of the right carpal 
joints as a ratio. There was no significant difference between the sum of the right 
carpal joint values and the left carpal joint values. The level of KS in the left 
radiocarpal joint was significantly higher than in the left midcarpal joint in all 
animals, p= 0.041, 95% Cl [1.015, -1.631]. The left radiocarpal joint was 
compared to the left tibiotarsal joint. Again there was no significant difference in 
the values obtained.
Each carpal joint value was compared as a ratio to the tibiotarsal joint on the 
corresponding side in all animals i.e. right radiocarpal joint versus right 
tibiotarsal joint, right midcarpal joint versus right tibiotarsal joint etc. Again, 
there was no significant difference between these paired fore and hind limb 
joints. There was a broad range of serum keratan sulphate values in the group of 
11 horses, (median 183 ng/ml, range 82-428 ng/ml), (Table 12).
Serum and the mean value of all joint values for each animal (Appendix 12) were 
compared to assess if there was any correlation between serum and synovial fluid 
in all animals. There was no correlation, (Figure 19), a finding that is in 
agreement with the results of other authors (Alwan and others 1990).
In conclusion, results obtained in this study of 11 animals show that there is a 
wide range in KS values between animals in the joints sampled. There does not 
appear to be any correlation between serum and synovial fluid KS levels 
measured in these horses. There appears to be no difference in KS values in 
paired carpal and tarsal joints between animals. There was a significant 
difference in the values obtained for the left radiocarpal joint compared to the left 
midcarpal joint between animals, in that KS levels were higher in this joint 
compared to the midcarpal joint in all animals. Horses No. 2, 8, 3 and 11 had 
values for the left radiocarpal joint that were more than twice the value of the 
corresponding midcarpal joint (Appendix 12). Grossly, these joints had been 
visually inspected and therefore, in these animals, the greater value cannot be 
explained on the basis of articular cartilage pathology or abnormal loading and 
wear on the joints.
56
JOINT
RATIO
MEAN
RATIO
95%
CONFIDENCE
INTERVAL
Level of 
signific.
BR/BL 0.92 0.57,1.27 NS
CR/CL 1.22 0.86,1.56 NS
ER/EL 0.99 0.83,1.14 NS
mBR+CR
mBL+CL 1.03 0.68,1.38 NS
mBR+BL
mCR+CL 1.11 0.91,1.31 NS
BR/CR 0.91 0.72,1.10 NS
BL/CL 1.32 1.02,1.63 p=0.041
BR/ER 1.05 0.74,1.35 NS
CR/ER 1.17 0.88,1.45 NS
BL/EL 1.26 0.97,1.55 NS
CL/EL 1.05 0.65,1.45 NS
Table 10
Normal equine paired joint ratios, (n=ll).
m = mean value. B= radiocarpal joint, C= midcarpal joint, E= tibiotarsal joint, R=right, L= left. 
NS= non-significant.
JOINT MEDIAN RANGE
BR 36,400 5,300 - 204,474
BL 49,293 5,086 - 193,043
CR 40,962 6,820- 185,139
CL 38,870 6,293 - 267,216
ER 57,619 6,631 -99,776
EL 59,270 7,163 - 144,333
Table 11
Median and range of KS values for individual joints in normal horses (n=ll).
B= radiocarpal joint, C= midcarpal joint, E= tibiotarsal joint.
R=right, L= left. Results are expressed as KS equivalents (ng/ml).
MEDIAN RANGE MEAN
± S D
Serum 183 82 - 428 215 ± 9 2
Table 12
Serum KS values for normal horses (n=ll). 
Results are expressed as KS equivalents (ng/ml).
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3. EXPERIMENT 2. DIURNAL VARIATION IN SERUM KS LEVELS. 
OBJECTIVES
In order to investigate whether there is diurnal variation in serum KS levels, six 
normal ponies, housed with no exercise, (Appendix 13) were sampled at 6 hour 
intervals (three times) within one day. These animals were defined as normal 
within the context of this study on the basis of no history of joint disease and no 
evidence of joint disease on inspection. Four fillies and two colts were used. The 
ponies were kept stabled with no exercise. The ponies were aged 15 to 16 
months. Blood samples were collected by jugular venepuncture (7 ml/sample) 
and processed as outlined on page 42. The ELISA was carried out as described 
earlier.
3.1. Results
Serum KS results are shown in Table 13. Results were plotted on a line graph 
(Figure 20). It was decided to analyse the data non-parametrically as one of the 
animals, No. 103, has very high serum KS values skewing the data, which did not 
appear normally distributed. A Kruscall-Wallis test was carried out, with a 
significance level p < 0.05 taken as statistically significant.
From Figure 20, there is graphical evidence that there was an increase in serum 
KS levels in two of the six animals between 10 am and 4 pm. In three animals, 
serum KS decreased between 10 am and 4 pm and in one animal there was no 
change.
Between 4 pm and 10 pm there was a decrease in serum KS as seen graphically 
in three of six animals. In two of six animals, there was an increase in serum KS 
and in one animal there was no change evident. The mean serum KS value 
between 10 am and 4 pm decreased by 6 per cent. Between 4 pm and 10 pm there 
was a 4 per cent increase in mean serum KS levels.
Statistically, there was no significant difference between values obtained at 10 
am and 4 pm and between 4 pm and 10 pm in all six ponies. There was no 
difference in values obtained at 10 am and 10 pm in all animals. There was a 
broad range of serum KS values in the six ponies at the various time intervals 
over the samping period (mean value, 166 ng/ml, range 70 to 451 ng/ml). This 
has also been observed in human studies investigating diurnal and day to day 
variation in serum KS levels (Block and others 1989). In conclusion, in the group 
of six ponies studied, there was no statistical evidence of diurnal variation in 
serum KS levels.
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4. EXPERIMENT 3. DAY TO DAY VARIATION IN SERUM KS LEVELS 
OBJECTIVES
Day to day variation in serum KS levels was investigated using a blood sampling 
protocol similar to that of Block and others (1989). Six ponies (same animals as 
in Experiment 2) were sampled (7 ml/sample) by jugular venepuncture on three 
separate occasions at 48 hour intervals. All samples were collected at the same 
time point (10 am) on each occasion. The animals were kept stabled during this 
period, with no exercise. Samples were processed as above.
4.1. Results
Due to the presence of very high values in one animal, (No. 103), which skewed 
the data, which did not appear normally distributed, non-parametric tests 
(Kruscall-Wallis) were carried out. The values obtained for each animal at the 
various time intervals are shown in Table 14. Values obtained were plotted 
graphically (Figure 21).
From the values plotted on the line graphs, there appears to be a decrease in 
serum KS levels in three of the six animals between Day 1 and Day 3. Two of the 
six animals showed an increase between Day 1 and Day 3, with one animal 
showing little or no change. Between Day 3 and Day 5, there was an increase in 
serum KS in four of the six animals, with a decrease in the remaining two 
animals.
Statistically, however, there was no significant difference between values 
obtained on Day 1, Day 3 and Day 5. In conclusion, there was no statistically 
significant evidence of day to day variation in serum KS levels in the group of 
animals studied.
PONY
NO.
10 AM 4 PM 10 PM
101 135 80 147
102 87 122 74
103 450 451 376
104 92 70 71
105 125 73 183
106 129 170 161
MEAN 170 161 169
Table 13
Diurnal variation in serum KS levels 
Results in ng/ml of KS equivalents.
PONY
NO.
DAY 1 DAY 3 DAY 5
lO l 135 141 168
102 87 99 120
103 450 430 364
104 92 67 136
105 125 127 100
106 129 72
99
MEAN 170 156 165
Table 14
Day to day variation in serum KS levels
Results in ng/ml of KS equivalents.
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ANIMAL MEAN ± S.D. RANGE Max.% change 
from mean
101 148 ± 14.4 135 - 168 13
102 101 ± 15.1 83 - 120 19
103 415 ±36.7 364 - 450 8
104 98 ± 28.5 67 - 136 38
105 117 ± 12.3 100 - 127 9
106 100 ± 23.3 72 - 129 29
Table 15
Day to day variation in serum KS (ng/ml), mean, standard deviation and range.
ANIMAL MEAN ± S.D. RANGE Max.% change 
from mean
101 121 ±29.2 80 - 147 21
102 94 ± 20.3 74 - 122 30
103 426 ± 35.0 376 - 450 6
104 78 ± 10.1 71-92 18
105 127 ± 50.0 73 - 183 44
106 153 +-18.0 129 - 170 11
Table 16
Diurnal variation in serum KS (ng/ml), n=6, mean, standard deviation and range.
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5. EXPERIMENT 4A
STUDIES ON SERUM KS IN EXERCISING HORSES 
OBJECTIVES
The purpose of this experiment was to determine the optimum time to blood 
sample normal horses post-exercise and evaluate whether serum KS levels were 
affected by a period of ’’acute" exercise.
5.1. Methods
An 8 years old Thoroughbred mare, used as a general riding horse / competition 
animal (eventer), exercised daily, was used as a control animal to determine if 
there was an optimum time to blood sample horses, following a period of acute 
exercise. This was carried out as a preliminary to taking samples from racehorses 
in training. The animal was selected on the basis of no history of joint disease or 
any form of orthopaedic injury. No joint abnormalities were detected on visual 
examination and palpation. There was no pain or lameness associated with 
flexion of the carpal, tarsal and metacarpophalangeal / metatarsophalangeal 
joints.
The animal was given a 45 min exercise session of trotting, cantering, jumping 
and galloping (moderate to high intensity exercise), rather than a standardised 
exercise test. All blood samples (10 ml/sample) were collected by jugular 
venepuncture into vacutainer tubes containing no anticoagulant. A blood sample 
was collected prior to the onset of exercise, and a second sample was collected 
immediately post-exercise. Further samples were collected at regular intervals up 
to 270 minutes post-exercise.
5.2. Results
Results are shown overleaf as ng/ml of KS equivalents. Results are plotted 
graphically in Figure 22. The first sample was taken at 10.30 am and subsequent 
samples were collected up to 4 pm. From the values obtained, the percentage 
changes calculated and the graphical evidence, it was concluded that a period of 
acute exercise appeared to cause an elevation in serum KS levels, (53 per cent 
change (increase) from baseline pre-exercise level) which took place during, or 
as an acute consequence of exercise in this animal. However, within 30 minutes 
of cessation of exercise, KS levels were starting to decrease and by 60 minutes 
post-exercise, values were only 9 per cent greater than the baseline value.
On the basis of these preliminary results, it was decided to bloodsample the 
group of racehorses in training immediately pre and post-exercise as well as one 
hour post-exercise to determine if acute exercise significantly affected serum KS 
levels in these animals.
TIME KS (ng/ml) % change 
from baseline
pre-exercise 141 100
(baseline)
5 min post 217 153
30 min post 159 113
60 min post 154 109
90 min post 153 109
150 min post 155 110
210 min post 97 70
270 min post 94 67
Table 17
Serial estimation of serum KS levels pre and post-exercise in one control animal.
All results are expressed as KS equivalents. The percentage change in serum KS from the 
exercise value (baseline denoted here as 100 per cent) is shown.
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6. EXPERIMENT 4B
INVESTIGATION OF THE EFFECT OF ACUTE EXERCISE ON SERUM 
KS LEVELS IN A GROUP OF RACEHORSES IN TRAINING
6.1. INTRODUCTION
A group of six racehorses in training were blood sampled before and after 
exercise to investigate whether there was any significant change in serum KS 
levels with a period of acute exercise. The age and sex of all animals was 
recorded (Appendix 14).
These horses were defined as normal within the context of the current study on 
the basis of no history of previous joint injury or other orthopaedic problems. On 
visual inspection and examination, there was no evidence of lameness or joint 
abnormalities, e.g. fluid distension or bone abnormalities. The animals were 
given a routine workout for that stable rather than a standardised exercise test. 
The exercise consisted of trotting, cantering and galloping for a period of 45 mins 
to 60 mins (moderate to high intensity exercise). All horses had been box rested 
the day prior to the test (trainer's day off).
The sampling time intervals for Test 1 were determined from the results of the 
one control animal exercised and serially sampled post-exercise. The racehorses 
were exercised and sampled on the same weekday as the control horse to 
eliminate any possible "day” effect. The pre-exercise sample was collected by 
jugular venepuncture from all animals in the same time period. A volume of 10 
ml of blood was collected on each sample occasion. A second sample was 
collected within 5 mins of cessation of exercise and a third one hour later. As the 
6 animals sampled were exercised in groups, the second and third samples were 
obtained over a four hour period, from 9.30 am to 1pm.
The experiment was repeated two weeks later (Test 2) on the same weekday, 
however, only four of the original six horses were available for sampling. It was 
decided, from analysis of the results (see Results section) obtained on the first 
exercise test, to sample these animals on two occasions, i.e. immediately pre­
exercise, and five minutes post-exercise. The horses were given the same 
exercise routine as on the first test occasion. Samples were stored at 4 °C on 
collection and were processed as described earlier (Experiment 1) within 3 hours 
of collection.
6.2. Results
The values of KS obtained on the exercise tests are shown in Tables 18 and 19. 
The values obtained for each animal are plotted in Figure 23 and Figure 24. The 
mean values for the two groups at each sampling time in Tests 1 and 2 are also 
plotted. From Figure 23 and Figure 24, there was a trend for serum KS levels to 
increase with a period of acute exercise. It was decided to analyse the data non- 
parametrically as in this small group of horses the data appeared to be skewed on 
normality plots. Previous studies in horses have assumed the data is normally
72
distributed (Alwan and others 1990; Yovich and Carroll 1991), however this was 
not the case in the current study. A Wilcoxon-signed Rank test was used (p value 
<0.05, 94% Cl).
Analysing results, there was a statistically significant increase between pre and 
immediately post-exercise values, p=0.036, median —30, 94% Cl [ -71, -13.5]. 
There was also a statistically significant increase between values pre-exercise and 
those obtained one hour post-exercise, p=0.036, median —32, 94% Cl [-73, -9]. 
There was no significant difference in values obtained immediately post-exercise 
and one hour post-exercise.
In Test 2, (n=4), there was an increase in serum KS levels as shown in Figure 24. 
This increase was however, not statistically significant.
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Horse Pre-exercise 5 mins post-exercise 1 hr post-exercise
No.l 69 90 77
No.2 58 140 136
No.3 65 71 75
No.4 52 73 74
No.5 70 130 138
No.6 53 92 95
MEAN 61 99 99
Table 18
Test 1. Serum KS levels in racehorses before and after a period of exercise (60 mins).
Results expressed as ng/ml of KS equivalents.
HORSE Pre-exercise 1 hr post-exercise
No.3 78 137
No.4 74 74
No.5 72 78
No.6 68 100
MEAN 73 97
Table 19
Test 2. Serum KS levels in racehorses (n=4) before and after a period of exercise (60 mins).
Results expressed as ng/ml of KS equivalents.
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CHAPTER IV
MEASUREMENT OF SERUM KS IN HORSES UNDERGOING SURGICAL 
TREATMENT FOR OSTEOARTHRITIS
1. OBJECTIVES
The objective in measuring KS in the three cases presented here was to monitor 
the effects of surgery on post-operative serum levels of KS and the response of 
the cartilage in the post-operative period. One animal was monitored for a period 
of fifteen weeks post-operatively, while the other two could only be sampled 
during their stay at Glasgow University Veterinary School (GUVS). Clinical 
history and findings are detailed as well as the measurements of KS.
2. SUBJECTS 
Case 1.
A five year old Thoroughbred flat racehorse was presented with a history of 
lameness and distension of the palmar and dorsal pouches of the left 
metacarpophalangeal joint one month previously following a race.
2.1. Examination
At examination, there was moderate distension of the palmar pouch of the joint 
with swelling and heat localised on palpation over the medial sesamoid bone. 
Direct palpation over the medial sesamoid and distal part of the medial branch of 
the suspensory ligament also elicited a pain response.
At walk, the animal did not appear lame, but at trot, there was a Grade 1 out of 5 
lameness evident (Stashak 1987). There was an obvious pain response on flexion 
of the joint and immediately following this flexion test, die horse was 1 XA out of 
5, to 2 out of 5 lame at trot.
2.2. Diagnostic procedures
A four point nerve block (palmar nerves anaesthetised just proximal to the palmar 
pouch of the metacarpophalangeal joint and palmar metacarpal nerves just over 
the button of the splint bone), did not improve the lameness, however, the animal 
was less painful on flexion of the joint and there was no increase in lameness 
following the flexion test.
Intra-articular anaesthesia of the affected joint was carried out, using 5 ml of 
mepivicaine (Intraepicaine, Arnolds Veterinary Products Ltd. U.K.) injected 
aseptically into the joint. Prior to injection of the local anaesthetic agent, a 
synovial fluid sample was collected (2 ml) and placed in EDTA for cytological 
evaluation and in a tube containing no anticoagulant for KS estimation. Cytology 
results are shown in Table 20. The synovial fluid sample appeared grossly 
normal. A sample was also taken for serum KS estimation. The horse was 
evaluated at walk and trot and the lameness was noted to have improved 
approximately 50 per cent. Ultrasonography of palmar metacarpal soft tissue 
structures was carried out and there was evidence of gross disruption of the linear
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ligament which was enlarged to twice its normal size. There was evidence of 
insertion sesamoiditis which was confirmed on radiography.
Standard views of the metacarpophalangeal joint were taken, as well as a flexed 
lateral view (Figure 25). Radiography revealed a severe advanced medial 
sesamoiditis with evidence of bone remodelling. A small, barely radiodense 
opacity was noted in the palmar pouch just at the point where articular cartilage 
stops and the soft tissues of the joint start on the palmar aspect of the third 
metacarpal bone. On close inspection of the apical part of the medial sesamoid 
bone, an old fracture bed was visible with evidence of one small chip in place.
2.3. Surgical treatment
Arthroscopy was carried out under general anaesthesia. Prior to distension of the 
joint, a synovial fluid sample was taken for KS evaluation. The arthroscope was 
placed in the medial palmar pouch of the joint. There was evidence of 
inflammation of the synovial membrane and palmar aspect of the third 
metacarpal bone. Debridement of the hypertrophied soft tissue in this area 
resulted in the removal of the small chip of bone seen on radiography. 
Examination of the medial sesamoid bone revealed extensive damage to the 
abaxial surface with loss of bone and disruption of the insertions of the 
suspensory ligament. Two small apical chip fractures were also removed. 
Curettage was carried out until healthy bone was identified and the joint was 
extensively lavaged. Further examination of the joint and palmar pouch did not 
reveal any other abnormalities. The horse was given 4.4 mg/kg body weight of 
phenylbutazone (PBZ), (Phenyzene, C-Vet Ltd. U.K.) intravenously prior to 
recovery from general anaesthesia. A Robert Jones bandage was placed on the 
affected limb and the animal confined to box rest in the post-operative period. On 
the first post-operative day, the horse was given 1 mg/kg body weight of PBZ 
(Equipalazone, Arnolds Vet. Products, U.K) orally twice daily, followed by 0.5 
mg/kg/body weight of PBZ orally twice daily for two further days. Post-operative 
recovery advice consisted of bandaging the affected joint for 6 weeks. Strict box 
rest was recommended for 14 days post-operatively, followed by in-hand walking 
for 5 to 10 mins twice daily, increasing to 20 to 30 mins twice daily. 
Approximately 6 weeks after surgery, the horse was turned out to grass.
Serum samples (10 ml) were taken for KS evaluation at 2 and 5 days post- 
operatively, while the animal was at GUVS, and then 7 days later, when the 
horse had returned to the training establishment. Serial samples were collected at 
14 day intervals on two further occasions until the animal was turned out to grass 
for an eight week period. It was not possible to collect samples for serum KS 
estimation from the horse during this time. A final sample was collected 
following the animal's return to training.
At the time of collection of the last sample, the horse had begun roadwork, 
consisting of daily walking and trotting, with a view to starting a career as a 
hurdler/chaser. The values of KS measured from the affected joint, and serum KS 
levels are shown in Table 21, together with the post-operative recovery 
programme. The data is shown graphically in Figure 26.
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RBC (xlO 12/L) 0.02
Hb (g/dL) 0.0
WBC (xlO 9/L) 1.9
Neutrophils 0.08
Lymphocytes 0.46
Monocytes 0.00
Basophils 0.00
Eosinophils 0.00
Macrophages 1.37
Table 20
Synovial fluid cytology results for Case 1.
Day of 
sample
KS equivalents 
(ng/ml)
Peri/post-operative
programme
Per
cent
change
from
baseline
D ay-3 74
2518(synovial)
pre-operative 68%
Day 0 
(Baseline)
108.24
3887(synovial)
intra-operative 100 %
Day 2 97 Box rest 89%
Day 5 81 Box rest 74%
Day 12 87 Box rest 80%
Day 14 Start walk-out, 5 min. BID *♦*
Day 26 102 Walking out in hand, 10 
min. BID
94%
Day 41 86 Walking out, 20 min. per 
day
80%
Day 42 **♦ Out to grass for 8 weeks ***
Day 106 40 Back in work one week 36%
Table 21
Pre and post-operative serum KS concentration for Case 1.
Key: ***=not blood sampled. Baseline (100 per cent) is the value obtained on the day of surgery.
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Figure 25. Flexed lateromedial view of the left metacarpophalangeal joint 
in Case 1. There is insertion sesamoiditis and a radiodense opacity in the palmar pouch of 
the joint just at the junction of the articular cartilage and soft tissues on the palmar aspect 
of the third metacarpal bone.
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2.4. Subject: Case 2
A 6 years old Thoroughbred mare, used for general riding purposes, was referred 
with a history of intermittent lameness of approximately 6 to 9 months duration. 
A tentative explanation for the onset of lameness was the occurrence of a fall 
while the animal was at grass.
2.5. Examination
At examination, there was evidence of mild left gluteal muscle atrophy. A pain 
response was elicited on flexion of the left metatarsophalangeal joint. There was 
no evidence of joint distension and no other abnormalities were detected in the 
limb. At walk, the animal was 1 out of 5 lame and this increased to 2 out of 5 
lame at trot. Following a flexion test on the left metatarsophalangeal joint, the 
lameness increased in severity.
2.6. Diagnostic Procedures
Standard radiographic views were taken of the affected joint. There was a medial 
plantar process fracture of the first phalanx (PI) visible on radiography (Figure 
27). This was associated with a lytic area surrounded by a sclerotic rim in the 
plantar process of PI. A diagnosis of DJD was confirmed on radiography. The 
right metatarsophalangeal joint was normal in appearance on radiography.
2.7. Surgical Treatment
Arthroscopy was carried out under general anaesthesia. Prior to joint distension, 
a 2 ml aliquot of synovial fluid was collected for KS estimation (tube containing 
no anticoagulant) and for routine synovial fluid cytology (EDTA). Cytology 
results are shown in Table 22. A blood sample (10 ml) was also collected for 
serr*n KS evaluation.
On arthroscopy, there was evidence of synovial proliferation within the joint and 
villous changes indicative of a chronic synovitis. The bone fragment was located 
in the distal portion (medial) of the plantar pouch and it was totally enclosed 
within the plantar synovial membrane. The fragment was removed by sharp 
dissection and the defect in the plantar process of PI was curetted down to fresh 
bleeding subchondral bone. Peterson and Ryden (1982) reported that Type 1 
osteochondral fragments located on the palmar aspect of the 
metacarpophalangeal joint could result in degenerative joint disease. The bone 
fragment was submitted for histopathology. The fragment was found to be 
composed mainly of dense, mature, poorly cellular but slightly disorganised bone 
tissue surrounded by dense collagen, containing occasional knots of bloodvessels. 
There was no evidence of an epithelial or synovial lining. There was no evidence 
of an inflammatory infiltrate. The joint was thoroughly lavaged, intravenous PBZ 
administered (as in Case 1) and routine post-operative care was given. The 
animal was confined to box rest and placed on a 3 day course of oral PBZ 
(lmg/kg body wt.) twice daily. Serial samples were taken for serum KS 
estimation at 2 and 4 days post-operatively until the animal was taken home and
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was no longer available for bloodsampling. The synovial fluid KS and serum KS 
results are shown in Table 23.
Post-operatively, the horse was box-rested for a further 7 days following return to 
its owner. Subsequently, in-hand walking exercise for 5 mins twice daily was 
begun. At 4 weeks post-operatively, the period of exercise was increased up to 15 
mins twice daily. The horse was then turned out to grass, and was placed back in 
a graduated exercise programme, not returning to full work for at least 12 weeks.
RBCx
1012/Litre
0.05
Hbg/dl. 0.0
W BCil09/Litre 0.2
Neutrophils 0.0
Lymphocytes 0.11
Monocytes 0.00
Eosinophils 0.00
Basophils 0.00
Macrophages 0.09
Table 22
Synovial fluid cytology results for Case 2.
Day Ks equivalents 
(ng/ml)
Peri/post op. 
programme
% change from 
baseline
Day 0 96
9,238(synovial)
Intra-operative
sample
100%
(baseline)
Day 2 175.7 Box rest 183 %
Day 4 124.8 Box rest 130 %
Table 23
Serum KS concentration (intra and post-operative) for Case 2.
The synovial fluid KS result is shown in brackets. Day 0 = the day of surgery and baseline (100 
per cent).
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Figure 27. Dorso-medial palmarolateral 45 ° oblique view of the left metatarsophalangeal 
joint for Case 2. There is a medial plantar process fracture on PI, associated with a lytic 
area surrounded by a sclerotic rim in the plantar process of PI.
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2.8. Subject: Case 3
A five year old Thoroughbred gelding, used as a Flat racehorse, was presented 
with acute onset, severe lameness which had started during training. The 
lameness was attributed to the right forelimb.
2.9. Examination
At presentation, the palmar pouch of the right metacarpophalangeal joint was 
distended. There was pain on flexion of the joint and increased lameness 
following a flexion test (2 out of 5 lame at trot prior to flexion of the affected 
joint increasing to 3 out of 5 lame at trot after flexion).
2.10. Diagnostic Procedures
Standard radiographic views were taken and there was evidence of some 
remodelling of the dorsomedial aspect of the first phalangeal bone (PI), on the 
dorsomedial articular rim of PI (Figure 28).
Intra-ardcular anaesthesia of the joint was carried out using 5 ml of mepivicaine 
(Intraepicaine, Arnolds Veterinary Products Ltd. U.K.). On examination at 20 
min post-injection of local anaesthetic, there was decreased pain on flexion and 
an improvement in the lameness to 1 out of 5 lame.
2.11. Surgical Treatment
A right dorsal metacarpophalangeal arthroscopy was performed. Prior to joint 
distension, a synovial fluid sample (2 ml) was taken and retained for KS 
evaluation. Arthroscopy revealed extensive remodelling of the dorsal aspect of 
PI with evidence, particularly to the medial aspect of the sagittal ridge, of 
cartilage damage. Opposite this area was a deep score mark on the medial aspect 
of the distal third metacarpal bone articulation with the metacarpophalangeal 
joint. There were linear "wear" lines on the medial aspect of the third metacarpal 
bone and evidence of enlargement of the dorsal capsule fibrous mass. There was 
also obvious villous hypertrophy. The cartilage lesions on the medial side of the 
dorsal aspect of PI were removed and the joint extensively lavaged. Intravenous 
PBZ was administered (as in Case 1 and 2). Routine post-operative care was 
administered (as already described) and the horse placed on a 5 day course of 
oral PBZ (lmg/kg body wt. twice daily). Samples were taken for serum KS 
evaluation at two and four days post-operatively (Table 24).
Day KS equivalents Peri/post-op.
programme
% change 
from baseline
Day 0 75.9
(3,272-synovial)
Intra-op. 100%
(baseline)
Day 2 169.3 Box rest 222.9%
Day 4 114 Box rest 154%
Table 24
Serum KS values (intra and post-operative) for Case 3.
Intra-operative synovial fluid KS concentration is shown in brackets. Day 0 : day of surgery.
85
Figure 28. Dorso-lateral palmaromedial 45 ° oblique view of the right metacarpophalangeal 
joint in Case 3. There is remodelling of bone on the dorsomedial aspect of the first phalanx, 
on the dorsomedial articular rim of the first phalanx.
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2.12. Results
In the three cases investigated, it was found that there was a significant increase 
in serum KS measured two days post-operatively in Cases 2 and 3, where serum 
KS had shown a change from baseline in Case 2 (85 per cent increase)and 123 
per cent increase over baseline with Case 3. However, by Day 4, the levels of 
serum KS in both horses had changed to 30 per cent greater than baseline (Case 
2) and 54 per cent greater than baseline (Case 3). With Case 1, the levels of KS 
measured in synovial fluid taken just before surgical intervention were 54 per 
cent greater than those measured 3 days prior to surgery and serum levels just 
before surgical intervention were 32 per cent greater than those taken pre- 
surgery. There was a decrease in serum KS levels from baseline at 2 and 4 days 
post-operatively. Over the ensuing sampling period post-operatively, serum KS 
values remained within ±10 per cent of the baseline value. There was no marked 
increase in serum KS values when the horse returned to walking exercise two 
weeks post-operatively. Synovial fluid cytology in the two horses sampled was 
within normal limits (Todhunter and Lust 1992). Serum KS values from the three 
horses were within the range of values observed in the group of racehorses in 
Experiment 4.
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CH APTER V
GENERAL DISCUSSION
1. THE ELISA ASSAY
1.1. Factors influencing the quantitation of KS in biological samples using the 
ELISA assay.
The development of highly specific immunoassays has provided a sensitive 
method for in vivo quantitation of KS in articular cartilage and serum 
(Funderburgh and others 1983; Thonar and others 1985; Ratcliffe and others
1988). These analyses are performed using a variety of different monoclonal 
antibodies specific for KS epitopes and quantitation of KS is achieved by 
comparison with cartilage PG standards from a variety of different animals and 
tissues. The ELISA in the current study uses a well characterised MAb 
(1/20/5D4) which has been shown to be highly specific for skeletal and corneal 
KS (Caterson and others 1983).
1.2. Characteristics of the KS epitope
The epitope region recognised by the MAb (1/20/5D4) consists of segments that 
contain at least three repeating units of sulphated galactose-sulphated 
acetlyglucosamine (Mehmet, Scudder, Tang, Hounsell, Caterson and Feizi 1986). 
These highly sulphated sequences have been determined to be located on the 
distal, non-reducing end of KS chains (Stuhlsatz, Keller, Becker, Oeben, 
Lennartz, Fischer and Greiling 1989). The epitope detected by this MAb is 
present only in the longest KS chains that represent less than 15 per cent of the 
total KS chains present in bovine nasal cartilage aggregating PGs. It has been 
suggested that a decrease in the size of die KS bearing molecule was 
accompanied by a decrease in the amount of KS epitope detected using a variety 
of MAb. Thonar and others (1991b), state that this does not appear to be a 
problem in the assay used in the current study, i.e. differences in the size of the 
molecules on which the epitopes are presented do not translate into differences in 
the amount of epitope detected. Evidence to support this is also found in the 
study of Thonar and others (1985), in which highly purified preparations of KS 
from human costal or bovine corneal tissue yield inhibition curves in an ELISA 
that are identical to those obtained using undigested PGs from these tissues.
It is assumed that the content of the KS epitopes and their presentation in the 
standard and unknown samples are similar. However, KS isolated from different 
animals and different tissues or at various developmental stages shows 
considerable variation in their biochemical analyses and their biophysical 
characterisation (Caterson and others 1989).
Several factors contribute to the structural heterogeneity of KS in biological 
samples and thereby influence the presentation of epitope for immunoassay. 
These include the degree of sulphation and the variable distribution of regions of 
the non, mono and disulphated disaccharide units within each individual KS 
chain (Oeben, Keller, Stuhlsatz and Greiling 1987). Variation in chain length
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with the possibility of multiple epitopes per chain (polyvalency) especially in the 
longer KS chains and the close attachment of a number of KS chains on a single 
polypeptide that may result in co-operative binding, will influence the results 
obtained (Caterson and others 1989). In the current study, the results of the spike 
assay were in agreement with the observations of Caterson and others (1989), 
demonstrating that the bivalent nature of the immunoglobulin molecule and the 
occurrence of multiple epitopes within the KS chain can affect the apparent 
quantitation of KS, leading to an overestimation of the quantity of epitope 
present. Their study also concluded that there may be differences in evaluating 
KS from normal and pathological specimens as the KS isolated from diseased 
samples may differ in both their chain size and in the relative abundance of a 
given epitope within the GAG chain.
When attempting to quantify KS, it must be borne in mind that it is only a 
proportion of the total KS that is actually being measured, i.e. the antigenic 
epitope recognised by the monoclonal being used in the assay (in this study, 
1/20/5D4). The amount of KS in a sample is referred to as nanogram equivalents 
of IRS, or WS (as used in the current study and referenced against IRS). Thonar 
(1989b), states that different anti-KS antibodies or different immunoassays using 
the same or different antibodies, can yield varying results. In the ELISA used in 
this study, he observed that when samples were pre-treated with papain, they lost 
no more than 35 per cent of their antigenicity. In contrast, when another 
monoclonal antibody, MZ15 was used in the same assay this loss of antigenicity 
became greater than 95 per cent. This must be borne in mind when comparing the 
results of different studies.
1.3. Volume turnover of synovial fluid in relation to quantifying KS 
Several factors govern the intra-articular concentration of macromolecules such 
as KS and other GAGs. These include macromolecule input rate, the flow of 
water across the synovial lining and the properties of the synovial intercellular 
matrix (Levick 1992). Macromolecule concentration is inversely related to the 
volume turnover rate, as the input macromolecule is constantly being diluted in 
the stream of synovial fluid passing through the joint cavity. This is especially 
important in arthritis where fluid turnover rates can be increased by 100 per cent 
to 300 per cent and where concentration values taken in isolation can be very 
misleading (Levick 1992). The time-averaged volume turnover is estimated to be 
2 to 4 pl/hr/cm2 in normal human and rabbit knees (Levick 1987). In human 
arthritis the average volume turnover rate increases significantly (Knox, Levick 
and Me Donald 1988), and this needs to be considered when interpreting intra- 
articular concentration data from affected joints. In both human and veterinary 
literature, KS is quantified in terms of ng per ml of KS equivalents rather than 
ng/ml of synovial fluid volume. The half-life of hyaluronan has been determined 
experimentally in horses (Levick 1992) in terms of volume flow and the effect of 
hyaluronan on the efflux of other macromolecules. Studies on KS in horses to 
date, however have not addressed the issue of the effect of synovial fluid volume 
(e.g. dilution effects in inflammatory arthritides/synovial effusion) or 
composition on results obtained. Efforts to quantify KS related to synovial fluid
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volume have concentrated on referencing KS to total SGAG (Alwan and others 
(1990) and Thonar and others (1991b), however, this does not imply that they are 
measuring identical pathological processes within the joint (Carroll 1989). 
Another possible means of quantifying KS measurements in relation to synovial 
fluid volume would be to use urea and albumin dilution techniques, which have 
previously been used in the horse to quantify bronchoalveolar lavage fluid 
volumes (Me Gorum, Dixon, Halliwell and Irving 1993).
1.4. Non-specific binding
It was thought that the highly negatively charged sulphated polyanion on KS 
would electrostatically interact with other biopolymers, however, the assay used 
in the current study has been shown to have no interference from electrostatic 
interactions and non-specific binding (Caterson and others 1989). Scott (1989) 
voiced the concern that in acute fulminating inflammatory conditions with gross 
cell destruction, liberation of usually highly cationic cell proteins could result in 
electrostatic interactions with the highly anionic KS epitope. However, Caterson 
and others (1989), have shown experimentally that the specific interaction of the 
monoclonal antibody with KS is very strong and that the possibility of non­
specific binding in this assay is minimal.
1.5. Matrix effect and interactions with factors in serum
It has been stated that possible interaction of unknown factors in serum with the 
MAb may result in masking of the epitope. Baker (1989) found that KS may 
ionically interact with high density lipoprotein in a potassium bromide gradient, 
suggesting that this interaction was not salt-concentration dependent and that 
other unknown factors were involved. The mechanism by which serum disturbs 
the response is unknown (Price and Newman 1991). It may affect the antigen- 
antibody response as suggested above, or the separation procedure. In the current 
study, there was strong evidence of non-parallelism between the standard curve 
and equine serum samples, which, (although it did not significantly affect the 
actual concentrations of KS measured) suggested that there may have been a 
matrix effect influencing the recognition and measurement of KS in equine 
serum.
1.6. Metabolism of KS
Proteoglycans, on leaving the synovial fluid compartment via the subsynovial 
lymphatics, may be further degraded before entering the blood, from which they 
are eliminated via the liver and kidneys (Thonar and others 1985). Exposure of 
terminal galactose residues on the KS chains and oligosaccharides results in a 
marked increase in the rate of elimination of fragments of all sizes, suggesting 
that binding of fragments to galactose receptors on hepatocytes represents an 
important pathway of elimination from blood (Maldonado and others 1989). KS 
fragments are also excreted in urine (Thonar and others 1989b). It may be 
advisable to evaluate liver function in order to accurately interpret serum KS 
levels, however, Thonar and others (1989b) state that serum KS levels are not 
affected to the same degree as hyaluronan, in the presence of liver disease.
90
Tests of liver function were not carried out in all animals used in the current 
study. Studies in human and veterinary literature have not addressed the potential 
effects of liver pathology on the metabolism of KS.
1.7. Discussion on the various methods used to assay KS in equine studies 
Alwan and others (1990) used an ELISA to measure KS similar to that used in 
the current study, except that microtitre plates were coated with equine articular 
cartilage PG monomer and a pure equine articular cartilage standard was 
included in each plate. The standard inhibition curve was constructed from values 
obtained by addition of horse KS standard to the coated plate in increasing 
concentrations. The monoclonal anti-KS antibody used was the same as in the 
current study.
Todhunter and others (1993) used an ELISA method which was essentially that 
of Thonar and others (1985), with minor modifications by Leipold and Lust 
(1989). They used pooled equine plasma as the calibrated control in the ELISA 
of plasma, and pooled equine synovial fluid as the control in the ELISA of 
synovial fluid samples. Their rationale for using these calibrated controls was 
that a significant number of the antigenic KS chains contain more than one 
epitope (Thonar and others 1991b), and KS chains in synovial fluid may contain 
different numbers of epitopes per molecule, compared with those in plasma. The 
slope of the control curve for the concentration of KS in plasma when plotted 
against optical density was less than when that of the synovial fluid KS was 
measured. An indirect method of establishing the concentration of KS in the 
controls was used as they suggested that the purified skeletal KS standard does 
not react strongly with the anti-KS monoclonal antibody in the ELISA. A 
possible explanation offered for this is that the conformation of the sulphate- 
oligosaccharide moieties on the KS, which are recognised by the antibody, have 
been altered during purification. This method involving the use of calibrated 
controls and indirectly establishing the concentration of KS in the standards has 
not been described elsewhere in the literature. The ELISA used in the current 
study, using WS referenced against IRS has been well described in human 
literature and widely used. In the current study, it was found to be reproducible 
from day to day, specific and reasonably sensitive, given the occurrence of 
polyvalency of die KS epitope (Caterson and others 1989), which is inherent to 
the KS molecule and is likely to be encountered using other assay methods.
1.8. Validation of the KS assay used in the current study
The inter-assay C.V. in the current study ranged from 10.5 per cent to 11.5 per 
cent. This corresponded well to that of Thonar (1993, unpublished data) which 
was 11.0 per cent. The fact that the interassay C.V. remained relatively consistent 
over the three batches of plates made, suggested that the uniformity of plate 
coating did not differ greatly from batch to batch. The intra-assay C.V. of 4.3 per 
cent was also acceptable (Thonar 1993 unpublished data).
Thonar and others (1991), report that repeated freezing and thawing and long­
term storage (up to 4 years) at —50 °C did not cause any loss of antigenicity of
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serum KS. In an earlier study, (Thonar and others 1985), it was reported that 
repeated freezing and thawing (storage temperature not specified), of serum or 
plasma did not in any way affect the level of serum KS measured (SD <2 per 
cent). In the current study, storage of serum at —20 °C for a period of 8 weeks 
resulted in a measurement that was 37 per cent less than the original 
measurement. Taking into account the allowed interassay C.V. of 10.9 per cent 
this measurement indicated deterioration in the sample over time. The sample 
stored at 4 °C gave a measurement 41 per cent less than that of the original 
sample. The sample stored at room temperature could not be assayed due to 
fungal contamination. From these results it would appear that it is preferable to 
store samples at a temperature of at least —50 °C to prevent deterioration in KS 
antigenicity.
In the spike assay, the addition of exogenous KS (WS) to equine serum and the 
increase recorded correlated with the findings of Seibel and others (1989), which 
showed that there were no blocking factors in serum from normal human 
patients. On both occasions on addition of the two spike samples of exogenous 
KS (WS) to equine serum samples, a reading greater than that expected occurred. 
The greater than predicted KS concentration may be explained by the fact that 
several domains of the KS molecule containing the epitopes recognised by the 
monoclonal antibody can occur in individual KS chains (Oeben and others 1987). 
Therefore there is a potential for the bivalent immunoglobulin molecule to bind 
more than one epitope in a given KS chain (Caterson and others 1989), leading to 
an overestimation of the amount of KS actually present. The magnitude of this 
overestimation has not been quantified to date and it is accepted that this is one 
limitation of the ELISA method used to measure KS.
2. STUDIES IN NORMAL HORSES
2.1. Experiment 1
Previous studies in horses have defined "normal" animals as those showing no 
evidence of lameness on clinical examination and no history of lameness (Alwan 
and others 1990). These authors also used synovial fluid samples and in some 
cases, radiography, to confirm that their horses had no joint abnormalities.
Yovich and others (1991) defined their normal horses as those that showed no 
evidence of lameness at trot, no synovial effusion from the midcarpal joint 
(the joint studied in lame animals) and no evidence of radiographic abnormalities 
on lateral, oblique, dorso-palmar and flexed lateral radiographic views of the 
carpus. Synovial fluid was also analysed from the midcarpal joint of normal 
horses for routine cytology and total protein, however, results were not shown 
and no correlation with KS results was carried out. In the study of Little and 
others (1990) normal joints were classified as those in which there was no sign of 
synovial effusion or pain during life, no radiographic abnormalities and grossly 
normal cartilage on post-mortem examination.
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In the current study, normal horses were defined as those which showed no 
evidence of lameness on clinical examination and no evidence of OA on gross 
inspection of the articular surfaces at post-mortem inspection. Although synovial 
fluid collected from each joint was visually inspected, cytological examination 
was not carried out. Alwan and others (1990) found that the mean number of 
synovial fluid white blood cells did not significantly differ between normal 
horses and those with OA, therefore, synovial fluid analysis was not routinely 
carried out in the horses used in this study for this reason and also for cost 
factors.
2.2. Definition of a ’’normal” joint
Poole and Meagher (1990), describe structural alterations known to occur in 
’’normal’’ equine joints. Small defects that appear as dimples or linear infoldings 
in the articular surface occur as a result of occlusion of blood vessels located 
within the cartilage canals of the articular cartilage. These lesions develop as a 
result of focal death and collapse of cartilage tissue in the radial zone of the 
cartilage during endochondral ossification. These defects arise during skeletal 
growth, are apparently unassociated with the develpoment of osteochondrosis 
and do not predispose to the development of OA. The pattern of scoring or 
’’wear’’ lines (Rooney 1969) occurs commonly in the metacarpophalangeal joint 
and metatarsopohalangeal joint, the radiocarpal and midcarpal joints and the 
tibiotarsal joints. They are found in mature horses of all ages and the mild form 
of the lesion, which is not necessarily progressive, is commonly observed at post­
mortem examination. However, at some stage, they can become symptomatic, 
resulting in OA. They are believed to be self-limiting, degenerative changes 
produced as a result of the effects of synovial fluid turbulence following habitual 
lines of movement within the joint (Rooney 1969). These changes within the 
joint are accepted as normal features and would not be visible on radiography.
2.3. Findings in normal horse joints
In Experiment 1, Horse No. 3 had one small dimpled lesion (4 mm diameter) on 
the medial articular surface of the right distal radius with a corresponding lesion 
of a similar size on the articular surface of the radial carpal bone. Horse No. 6 
had a dimpled area (5mm) on the articular surface of the ulnar carpal bone, seen 
when the right radiocarpal joint was opened. In these two animals, the KS levels 
recorded for these joints were not greater than those from the contralateral joint 
(Horse 3) and in Horse 6, levels from the right radiocarpal joint were very similar 
to those from the left radiocarpal joint. The contribution of these wear and tear 
lesions to the levels of KS released from or turned over in the joint is unknown. 
Although the clinical features of normal horse joints are reasonably uniform, 
there is variation in the articular cartilage within the range of ’’normal’’ that may 
influence the KS measurements obtained from these joints. However, in the 
current study, it did not appear to make a difference to the results obtained.
In the group of eleven normal horses in Experiment 1, there was no significant 
difference in the values obtained from paired carpal and tarsal joints. The wide
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range of variation in the measurements obtained from each joint may reflect the 
fact that the population of animals sampled was heterogenous in relation to age 
and use, and also parallels the wide range of serum values reported in both 
normal humans (Thonar and others 1985) and horses (Alwan and others 1990). 
Hascall and Giant (1987) suggest that the extent and degree of sulphation may 
vary considerably from person to person, possibly accounting for the wide range 
of variation seen in serum samples. This may also be the case with equine 
synovial fluid and serum samples. Yovich and others (1991) found that synovial 
fluid KS values ranged from 62,200 ng/ml to 151,500 ng/ml, median 101,100 
ng/ml in the midcarpal joint in a group of normal horses (n=19). Right and left 
midcarpal joints in these horses were not compared. In the current study, KS 
values for the midcarpal joints varied from 6,820 to 185,139 ng/ml, median 
40,962 ng/ml, (right midcarpal joint) to 6, 293 to 267,216 ng/ml, median 38,870 
ng/ml (left midcarpal jo in t). These values are not directly comparable to those of 
Yovich and others as the populations of animals were different, the criteria for 
assessing normality were dissimilar and different assays were used. The modified 
DMB assay measures all sulphated GAG, which differs from the immunoassay in 
the current study which is quantitating only the KS epitope recognised by the 
MAb.
In the study of Alwan and others (1990), carpal joint KS values ranged from
3,000 ng/ml to 80,000 ng/ml with a mean value of 20,800 ng/ml. Again, paired 
joint values were not assessed in the thirty normal joints sampled, nor were the 
carpal joints assayed specified in terms of the actual compartment, (radiocarpal 
or midcarpal joint), from which the fluid was obtained. Serum values of KS in 
normal horses ranged from 90 ng/ml to 6,800 ng/ml compared to 82 to 428 ng/ml 
in the current study. Again, it is difficult to draw comparisons between the actual 
values obtained as, although the format of the ELISA used is similar, the 
standards used as reference antigen differ from those used in the current study 
and the population of animals from which these samples are taken may differ in 
terms of criteria used to define "normality". However, irrespective of the methods 
used to measure KS, all studies described in horses generally seem to show that a 
wide range of values may be found in normal animals.
In the current study, there was an increase in 8 of the 11 horses in the level of KS 
measured in the left radiocarpal joint compared to the left midcarpal joint. It is 
difficult to explain why this is the case in this group of horses, as there was no 
evidence of e.g. acute articular cartilage injury or pathology that may have 
accounted for an elevation of KS in the synovial fluid of these animals. It was 
noted that three of these horses had values for the left radiocarpal joint that were 
more than double the values for the corresponding midcarpal joint and these 
animals may have biased the data in the small sample number used here. It would 
be interesting to evaluate whether this elevation in KS was present in a larger 
population of normal horses than those examined here.
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2.4. Diurnal and day to day variation in serum KS levels 
In the group of six ponies studied in Experiment 2, there was no evidence of 
diurnal or day to day variation in serum KS levels. This finding in horses was 
similar to that of Block and others (1989) wherein serum levels of KS in humans 
carrying out normal activity did not vary significantly during the course of a 
single day or from day to day over a period of one week. Analysis of mean KS 
levels comparing each time period did not reveal any significant changes in KS 
concentration during any specific time of day or day of the week in human 
subjects. This was also the case in the population of ponies studied here. The 
maximum temporal variation in any given pony in this group was 38 per cent in 
the day to day study and 44 per cent in the diurnal study. This was considerably 
higher than in the human study where the maximum temporal variation was 10 
per cent, and this figure was used as the basis on which to state that a single KS 
measurement was representative of a stable and unchanging KS serum 
concentration. In the study of Block and others (1989), subjects were allowed to 
carry out moderate exercise, which may have affected the clearance rate of KS 
from synovial fluid to serum and possibly its metabolism. In the current study, 
the ponies were restricted to no exercise while samples were being collected and 
this may account for the difference in results compared to those of Block and 
others (1989).
It was observed in the current study that Pony No. 103 had serum KS levels that 
were significantly higher (e.g. 415 ± 36.7 ng/ml of KS equivalents in the diurnal 
variation study) compared to the other animals, e.g. Pony No. 104 (98 ± 28.5 
ng/ml of KS equivalents). Pony No. 103 also had serum KS values in the day to 
day variation study that were markedly higher than the other animals in the 
group. Although these ponies had no history of joint disease and no evidence of 
joint disease on inspection, it may be possible that this animal had undetected 
joint disease. May (1993 unpublished) has stated that there may be an inherited 
biochemical abnormality of cartilage in horses, accounting for OA changes seen 
in unbroken animals as young as two years of age. This may be another possible 
explanation for the high serum KS levels in this animal. In the absence of OA, it 
may be likely that very high circulating levels of KS in this pony may be due to 
individual biologic variation, however, there is no data available currently on 
serum KS levels in a large group of young unbroken animals to determine if this 
is in fact the case.
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2.5. Effects of exercise on serum KS levels
In the group of six horses studied in Experiment 3, there was a significant 
increase in serum KS levels post-exercise on the first exercise test. This increase 
was not observed on the second exercise test, in which only four of the original 
six animals were available for blood sampling. However, trends showed that 
there was a graphically evident rise in serum KS comparing pre and post-exercise 
values. It would be desirable to study a larger group of animals on another 
occasion to ascertain if the elevation in serum KS levels with exercise is 
repeatable. It has been reported in humans by Block and others (1988), that 
serum KS levels do not increase with moderate exercise and by Thonar and 
others (1991) that strenuous exercise, (i.e. running a marathon) does not result in 
a significant increase in serum KS levels. It was noted that the baseline serum KS 
values in these horses did not vary on the first and second sampling occasions, 
which were carried out on the same week day (two weeks apart) to eliminate a 
"day” effect. This showed that the levels of serum KS did not vary greatly from 
week to week in this study.
2.6. Studies in horses with osteoarthritis
In the study of Todhunter and others (1993), ponies undergoing surgery to create 
osteochondral defects in the radiocarpal joint were exercised at five days post- 
operatively, while on medication with PBZ. Plasma KS levels peaked two days 
after joint injury in all ponies and were lowest twenty one days after joint 
treatment. In two of the three cases of chronic joint disease (three to six months 
duration) described in the current study, serum KS levels were significantly 
elevated two days after surgery, which was similar to the findings of Todhunter 
and others (1993) and were starting to decrease by day four post-surgery (Case 2 
and 3). With Case 1, serum KS levels were not elevated two days post- 
operatively, but started to decrease 5 days post-operatively. It is difficult to 
explain why this horse had an elevated synovial fluid and serum KS value on 
Day 0 compared to 3 days pre-surgery as there was no evidence of iatrogenic 
damage to the articular cartilage as a result of intra-articular anaesthesia at 
arthroscopy and the procedure had been carried out as atraumatically as possible. 
It is unlikely that the anaesthetic agent used (mepivicaine) had any adverse effect 
on the articular cartilage or synovial membrane that would result in a measurable 
increase in KS. This horse was monitored to 106 days post-operatively and serum 
KS levels remained reasonably consistent in the post-operative recovery period. 
The horses in this study were on a similar treatment regime with PBZ as those of 
Todhunter and others (1993). The pharmacokinetics of PBZ in equine synovial 
fluid and its effect on synovial metabolism is currently unknown. Similarly, the 
effect of PBZ on equine PG synthesis is also unknown. A potential exists for 
monitoring the effects of PBZ in conjunction with post-operative management 
programmes, using KS as a marker of articular cartilage metabolism.
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C H APTER VI
C O N C L U SIO N S
1. APPLICATION OF THE KERATAN SULPHATE ASSAY 
Several studies (Thonar and others 1985; Carroll 1989; Sweet and others 1988) 
have suggested the measurement of serum KS has potential for diagnosis of OA 
in man. However, the accuracy of the assay relies on several factors including 
size and degree of sulphation of the KS epitopes in serum from OA patients 
(Caterson and others 1989) which may differ from KS epitopes in healthy 
subjects. It has been concluded from studies on humans with various arthritic 
disorders that estimations of KS have not proved to be true diagnostic assays as 
they only retrospectively confirm pre-existing diagnosis (Caterson and others
1989). As studies have shown (Ratcliffe and others 1988; Todhunter and others 
1993), KS levels are elevated in the acute stages of joint injury compared to the 
more chronic stages. The level of KS in advanced OA therefore has little 
relevance to the performance horse. It only retrospectively confirms a diagnosis 
of OA which has already compromised the animal's athletic ability, at a stage in 
the disease process where treatment may not render the joint fully functional.
In the study of Alwan and others (1990) and Yovich and others (1991), there was 
no difference in KS levels measured from normal joints and joints with OA. 
However, the chronicity of the condition and the severity of clinical signs were 
not staged, so it is difficult to interpret these findings. Careful selection and 
definition of patient groups is an important factor in the meaningful interpretation 
of KS results in both human and equine studies. It is also important to bear in 
mind that the contribution of KS released with normal metabolism in the joint to 
the quantity of KS measured at any given sampling time in clinical cases of OA 
is unknown. Brandt (1991) voices this concern, however the issue has not, to date 
been addressed in human and veterinary studies. Development of a panel of 
monoclonal antibodies that identify anabolic markers synthesised in OA could 
potentially address this problem in a more satisfactory manner.
Tests such as the KS assay may provide information on the activity of disease 
and possibly on the prognosis and response to therapy, however, they do not, at 
this time, provide a diagnosis of the type of disease activity affecting the joint on 
their own (Todhunter and others 1993). If this assay is to be used to evaluate 
articular cartilage status in OA, it would be best to use it in conjunction with 
other biochemical markers as outlined in Chapter I. Using multivariate statistical 
analysis, a combination of these variables would be useful in providing a more 
accurate prognosis.
It would also be important to consider the effects of various assay methods on the 
interpretation of KS results in human and equine studies. With regard to equine 
assays, it would be advisable to standardise the ELISA method used as much as 
possible in terms of standard used to produce the standard curve and the MAb
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used so that results could be meaningfully interpreted and referenced against 
those from other institutions. The assay used in the current study was essentially 
that of Thonar and others (1985), which is widely used in human medicine and 
results were reproducible from day to day. It may be advisable to use equine 
cartilage standards in the ELISA to measure KS in equine samples to reduce the 
possibility of species differences in KS affecting the recognition of epitope. It 
may also be useful to prepare equine standards in KS-depleted equine serum 
(using solid phase antiserum to adsorb KS) to reduce the possibility of a matrix 
effect.
2. POTENTIAL FUTURE APPLICATIONS OF KERATAN SULPHATE 
MEASUREMENT IN HORSES
A potential use for monitoring KS may arise in longitudinal blood sampling of 
racehorses during training to identify animals at possible risk of developing OA. 
The wide range of serum KS levels in the equine population in the current study, 
also reported by other workers, would suggest that in any future investigations, 
longitudinal studies, where each animal provides its own baseline values, should 
be carried out. It would be ideal to sample these animals prior to commencing a 
period of training in order to establish baseline values with which to compare 
results obtained throughout a subsequent work programme. It is known that the 
content of KS in articular cartilage increases with exercise (Jones, Torssan and 
Lamperg (1977). It would be important to establish a data base of longitudinal 
sampling results on young, unbroken Thoroughbred horses (not destined for 
racing) with which to compare data from unbroken racehorses of a similar age 
group that subsequently undergo a training programme in order to evaluate the 
effect of an exercise regime on KS levels compared to a control group. The 
current study has shown that there is no diurnal or day to day variation in serum 
KS levels in normal animals, and that as such, measurements of KS represent a 
steady state.
Monitoring serum KS may also be beneficial in attempting to elucidate the 
possible reasons for the appearance of OA in young unbroken animals, which has 
been suggested as an inherited biochemical abnormality. It would be important 
however, to have sufficient age matched ’’control” horse sampling data in order to 
differentiate possible early OA KS levels from age-related changes in serum KS 
which are known to occur in humans (Sommarin and Heinegard 1986; Thonar 
and others 1990) but which have, as yet, not been investigated in the horse.
3. FUTURE TRENDS IN PROTEOGLYCAN ASSAYS
Current research in human medicine is targeting on neoepitopes generated by 
individual enzymes involved in the PG degradation process. Efforts are being 
concentrated on the development of a panel of monoclonal antibodies specifically 
directed against the new N and C terminal domains generated by the degradation 
of cartilage generated by extracellular metalloproteinases. Metalloproteinases can 
be detected by immunoassay, but this does not take into account whether these 
enzymes are active, or the presence of inhibitors which neutralise their activity. 
The immunological detection of enzyme-derived epitopes is directly related to
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the degree of specific involvement of individual proteases. Development of a 
panel of monoclonal antibodies could be used to detect the enzymes involved in 
cartilage destruction (Caterson 1991). Current research is also concentrating on 
anabolic markers found in newly synthesised PG which occur as a result of the 
chondrocyte's attempts to repair and remodel the connective tissue around it. In 
addition there are anabolic markers present at an early stage of the disease 
process before there is any significant loss of PG from the tissue or any evidence 
of cartilage destruction (Caterson, Mahmoodian, Sorrel and others 1990). These 
offer some potential for truly early diagnosis of OA preceding the onset of 
clinical signs.
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APPENDIX 1 Suppliers of reagents and materials
Arnolds Veterinary 
Products Ltd., 
Shrewsbury,
U.K.
A/S NUNC 
Kamstrupvej 90, 
Kamstrup DK-4000, 
Roskilde,
Denmark.
Beckman Ltd.,
Progress Road,
Sands Industrial Estate, 
High Wycombe,
Bucks.,
U.K.
C-Vet Ltd.,
Minster House,
Western Way,
Bury St. Edmunds,
U.K.
Dynatech Laboratories 
Daux Road, 
Billingshurst,
West Sussex,
U.K.
ICN Biomedicals Ltd., 
Eagle House,
Peregrine Business Park, 
Gomm Road,
High Wycombe 
U.K.
MSE
Manor Royal,
Crawley,
Sussex,
U.K.
Intraepicaine
Equipalazone
ELISA plates.
Centrifuge tubes and rotors
Phenyzene
Plate reader and computer 
software
Chondroitin ABC lyase 
1/20/5-D4 monoclonal 
antibody 
Plate sealers 
Titertek pipette
Tube piercer.
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Minitab (Release 9 for Windows), Minitab statististics
Clecom Microcomputer Specialists, package
The Research Park,
Vincent Drive, Edgbaston,
Birmingham,
U.K.
Paar Scientific Ltd.,
594 Kingston Road, 
Raynes Park,
London.
U.K.
Pierce and Warriner, 
Chester,
U.K.
Pierce U.K. Ltd.
36, Clifton Road, 
Cambridge,
U.K.
Sigma Chemical Co. Ltd., 
Fancy Road,
Poole, Dorset,
U.K.
Paar digital density meter.
Guanidine hydrochloride 
(Sequanal grade)
Dialysis Membrane. 
Vol./cm. 7 ml.
MW: 6000-8000.
General chemicals
Scotlabs., TrefF tubes
Wishaws Road, Coatbridge,
Strathclyde,
UK
Scottish Antibody Production Unit. SAM-HRP Anti-mouse Ig G.
Law Hospital,
Carluke,
Lanarkshire,
U.K.
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APPENDIX 2.
Buffer composition for proteoglycan purification. 
Buffer for cartilage.
TRIS BUFFER
Trisma base 
Sodium chloride 
EDTA
Sodium azide(w/v)
Adjust pH to 4.3
SODIUM ACETATE BUFFER 
100 mis contains:
Sodium acetate trihydrate 0.05M
6-amino caproic acid 0.10M
EDTA 0.10M
Benzamidine 0.005M
7.5 M GUANIDINE HYDROCHLORIDE SOLUTION 
100 mis contains:
Guanidine hydrochloride 7.5M
EDTA 0.1M
6-amino caproic acid 0.1M
Benzamidine 0.005M
DIALYSIS SOLUTION 
500 mis contains:
Sodium acetate 0.05M
EDTA 0.10M
6-amino caproic acid 0.10M
Benzamidine 0.005M
0.05M 
0.15M 
0.01M 
O.Olper cent
0.61 g/L. 
8.77 g/L. 
3.72 g/L. 
0.10 g/L.
0.68 g.
1.31 g. 
0.37 g. 
0.078 g.
57.32 g. 
0.37 g. 
1.31 g 
0.078 g.
3.40 g.
1.86 g.
6.56 g. 
0.39 g.
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APPENDIX 3
C alculation of the theoretical grad ien t form ed during  associative and 
dissociative density g rad ien t centrifugation.
— ^density gradient at the position ro , the centre of the Gaussian band. 
dr
—  = -------- = (angular velocity)2 x density gradient at position ro
dr B( p)
B=  A function of the tem perature, activity, m olecular w eight and partial 
specific volume o f the solute at a density p.
B is evaluated by graphical methods from published data o f  densit ies  (Ifft et al, 
1 9 6 1 ) and activity coeff ic ients .
Associative Density Gradient calculations.
p o — 1.69 g /ml. M ax im um  rotor speed = 37,  5 0 0  rpm.
dp (37500 j2 x 6.271 x 0.010966
—  = ---------------------------- o--------------g / ml / cm
dr 1.190.<109
= 0.0813
Therefore, p m a x .-  1.69 + (0.0813x 1.938)
=1.85 g / nil.
w =  angluar velocity.
Rotor type used: Beckman Ti 60.
p m i t i =  1.69- ( 0.0813x 2.17) 
= 1.51 g / ml.
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Dissociative Density Gradient calculations.
p o =  1.5 g /ml. Maximum rotor speed= 37,  500  rpm.
Therefore,
dp (37500)2 « 6.271 x 0.010966
—  =     <> / ml / cm
dr 1.245 x 10
= 0 .0777 .
Therefore, p  m a x .-  1.5 + ( 0 . 0 7 7 7  x 1.938 )
= 1.65
/; min..= \ .5-(0.0111 x 2,17 )
-  1.33
APPENDIX 4
Buffer preparation for plate coating
Chondroitin ABC lyase buffer.
Volume prepared = 100 mis.
Sodium acetate 0.1 M 0.22 g/100 mis.
.22 g/100 mis.
Tris 0.1 M 1.21 g/100 mis.
Adjust pH to 7.3 using conc.HCl.
Plate coating buffer.
Volume prepared = 1 litre.
Sodium carbonate 20 mM 1.12 g/L.
Sodium bicarbonate 20 mM 1.68 g/L.
Sodium azide 0.002 % 20 mg/L.
Adjust pH to 9.2 using conc. HCL.
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APPENDIX 5
Buffer for preparation of MAb stock.
PBS buffer for dilution of Mab to make a 1/100 dilution of MAb.
Per litre of MAb buffer:
Sodium chloride 120mM 54.55g.
Disodium hydrogen orthophosphate 5mM 0.7 lg.
EDTA lOmM 3.72g.
Trizma base 0.5 ml per Litre.
Adjust pH to 7.0 using conc.HCl.
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APPENDIX 8
JOINT NAMING CODE 
Mark left limb joints as (L) and right limb joints as (R). 
A= metacarpophalangeal joints.
B=radiocarpal joints.
C=intercarpal joints.
D=metatarsopophalangeal joints.
E=tibiotarsal joints.
SE=serum.
Example:
Horse No.l. (Number corresponds to the horse's owner). 
Right fore radiocarpal joint=lBR.
Serum sample from No.l=lSE.
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APPENDIX 9
Composition of buffers and reagents used in the KS ELISA.
Phosphate buffered saline used for sample, standard and antibody dilution and for 
plate washing.
PBS stock solution (lOx)
Potassium chloride 0.026M
Potassium dihydrogen phosphate 0.015M 
Sodium chloride 1.37M
Disodium hydrogenorthophosphate 0.08M 
(anhydrous).
Prepare a 1 in 10 dilution of the stock solution as required using distilled water. 
Working buffer
Phosphate buffered saline , 0.05 per cent Tween 20 (0.5 ml of Tween-20 /L of 
PBS.)
Adjust pH to 5.3 using conc. HC1.
PBS-Tween 20,1 per cent BSA, pH 5.3 (antibody buffer)
100 ml of PBS contains lg of Bovine Serum Albumin (BSA).
This buffer is used for all antibody dilutions.
Volume made up=l L.
Citrate / Phosphate buffer 
Volume made up=200 ml.
Citric acid 0.05 M 1.05 g/lOOml.
Disodium hydrogen orthophosphate 0.10 M. 1.42 g/lOOml.
Components are made up in distilled water. 100 ml of citric acid is added to 
approximately 90 ml of disodium hydrogen orthophosphate and adjusted to pH
5.0 using the remainder of the disodium hydrogen orthophosphate. The buffer is 
stored at 4 °C.
OPD colour reagent
The colour reagent is made up immediately prior to use. The citrate phosphate 
buffer, stored at 4 °C is first allowed to come to room temperature.
To 25 ml of citrate / phosphate buffer add a 10 mg tablet of o-phenylene diamine 
and 11 pi of 30 per cent hydrogen peroxide. The colour reagent should be tested 
prior to use by adding a small amount to the SAM-HRP preparation and 
observing the colour change to orange-brown within 5 seconds.
2g /litre. 
2g /litre. 
80g /litre. 
11.4g /litre.
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APPENDIX 11
CASE INFORMATION (EXPERIMENT 1)
Horses classified as "normaTin the current study were those euthanased for reasons other than 
joint disease, with no history of joint disease and no evidence of lameness or joint distension on 
examination. All joints were opened and visually inspected at post-mortem examination. Cases 
were from the Equine Clinic (Medicine) at Glasgow University Veterinary School, except 
No.ll (Royal (Dick) School of Veterinary Studies).
No. Case
Source
Age
(years)
Sex Breed Use Cause of 
Death
1 Medicine 4 Mn Clyde UB Grass sickness
2 Medicine 2 Mn TBx UB Colic
3 Medicine 14 F TBx RIH Squamous cell 
carcinoma
4 Medicine 4 F Clyde UB Colitis
5 Medicine 7 Mn TB NHRH Colic
6 Medicine 15 F Pony RIH Chronic
diarrhoea
7 Medicine 5 F Pony RIH Grass sickness
8 Medicine 7 Mn TBx RIH Grass sickness
9 Medicine 5 Mn TB FRH Tendon injury 
(chronic)
10 Medicine 8 Mn TBx RIH Colic
11 R(D)SVS 4 Mn TB HU Colic
Mn=gelding, F=mare, TB=Thoroughbred, TBx=Thoroughbred cross, 
Clyde=Clydesdale, UB=unbroken, FRH=Flat racehorse, NHRH=National Hunt 
racehorse, RIH=Riding horse, Hu=Hunter.
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APPENDIX 12
Normal horse joint and serum KS data 
Results expressed as ng/ml of KS equivalents
NO. BR BL CR CL ER EL SE
1 109,990 68,518 106,564 72,247 87,342 90,150 163
2 120,678 193,043 129,584 111,856 96,798 144,333 254
3 36,400 88,780 40,962 43,232 57,619 59,270 428
4 204,474 182,494 185,139 267,216 99,776 100,429 332
5 29,923 24,716 16,081 13,802 17,667 14,527 209
6 5,300 5,086 6,820 6,293 6,631 7,182 150
7 95,194 49,293 109,413 38,870 90,281 101,865 183
8 43,032 136,250 49,968 79,363 86,211 84,720 182
9 8,382 15,486 16,455 15,249 8,505 12,778 82
10 11,166 10,204 12,020 9,913 10,613 7,163 140
11 5,762 14,165 10,338 9,363 11,483 10,870 246
KEY: B= radiocarpal joint. C= intercarpal joint. E= tibiotarsal joint. 
SE= serum.
R= right limb.
L= left limb.
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APPENDIX 13
PONY INFORMATION (ANIMALS USED FOR DAY TO DAY AND 
DIURNAL VARIATION STUDIES).
All ponies were aged 15 to 16 months old. All were Shetland ponies.
Animals were housed with no exercise. These animals were being used as part of another study, 
under Home Office licence, and "leftover" serum from that experiment was used in the current 
study.
Pony No. Sex
101 M
102 F
103 M
104 F
105 F
106 F
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APPENDIX 14 
Racehorse data
Horse No. Breed Age Sex Use
1 TB 10 MN FRH
2 TB 2 F FRH
3 TB 3 F FRH
4 TB 2 MN FRH
5 TB 3 MN FRH
6 TB 3 F FRH
TB= Thoroughbred, F= Mare, Mn= Gelding, FRH= Flat Racehorse.
116
GLOSSARY
A1D1 Associative 1, Dissociative 1.
ADGC Associative Density Gradient Centrifugation.
CS Chondroitin Sulphate.
CLYDE Clydesdale.
C.V. Coefficient of Variation.
DDGC Dissociative Density Gradient Centrifugation.
DJD Degenerative Joint Disease
DMB Dimethylene Blue.
ELISA Enzyme Linked Immunosorbent Assay.
ESE Equine Serum.
ESF Equine Synovial Fluid.
F Female.
FRH Flat Racehorse.
GAG Glycosaminoglycan.
HSE Human Serum.
HSF Human Synovial Fluid.
HU Hunter.
IL-1 Interleukin-1.
IRS International Reference Standard.
KS Keratan Sulphate.
M Colt.
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MAb Monoclonal Antibody.
mins minutes.
ml mililitres.
MN Gelding.
ng Nanograms.
NHRH National Hunt Racehorse.
OA Osteoarthritis.
OCD Osteochondrosis.
OD Optical Density.
OPD 0-phenylene diamine.
PBS Phosphate Buffered Saline.
PBZ Phenylbutazone.
PG Proteoglycan.
PAI-1 Plasminogen Activator Inhibitor-1.
PSGAG Polysulphated Glycosaminoglycan.
QCS Quality Control Serum.
RIH Riding Horse.
SAM-HRP Sheep Anti-Mouse IgG Horseradish Peroxidase.
TB Thoroughbred.
TBx Thoroughbred cross.
TGFB Transforming Growth Factor Beta.
TNF Tumour Necrosis Factor.
UB Unbroken horse.
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WS Working Standard.
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